{
    "Sponsor Confidentiality Statement ": {
        "name": "Sponsor Confidentiality Statement ",
        "data_type": "Text",
        "definition": "C181236\nFor review purpose, see definition of the controlled terminology below:\nA written message within the study protocol that asserts a statement of non-disclosure, such that information contained within the protocol document may only be shared with authorized parties.",
        "guidance": "Insert the Sponsor\u2019s confidentiality statement, if applicable, otherwise delete.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C181236",
        "repeating": "No"
    },
    "Full Title ": {
        "name": "Full Title ",
        "data_type": "Text",
        "definition": "C132346\nFor review purpose, see definition of the controlled terminology below:\nThe formal descriptive name for the protocol sufficient to describe key elements of the study, aimed at a scientific audience.",
        "guidance": "The protocol should have a descriptive title that identifies the scientific aspects of the trial sufficiently to ensure it is immediately evident what the trial is investigating and on whom, and to allow retrieval from literature or internet searches.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "Title page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Sponsor Protocol Identifier\nConcept: C132346",
        "repeating": "No"
    },
    "Trial Acronym": {
        "name": "Trial Acronym",
        "data_type": "Text",
        "definition": "C94108\nFor review purpose, see definition of the controlled terminology below:\nAcronym or abbreviation used publicly to identify the clinical trial.",
        "guidance": "Acronym or abbreviation used publicly to identify the clinical trial. Delete this line from the table if not applicable.",
        "conformance": "Optional ",
        "cardinality": "One to one",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: C94108",
        "repeating": "No"
    },
    "Sponsor Protocol Identifier": {
        "name": "Sponsor Protocol Identifier",
        "data_type": "Text",
        "definition": "C132351\nFor review purpose, see definition of the controlled terminology below: \nA unique code assigned by the Sponsor that identifies a specific protocol. ",
        "guidance": "A unique alphanumeric identifier for the trial, designated by the Sponsor.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "Title page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading\nConcept: C132351\nNote: Must have at least One Character May not be (null)",
        "repeating": "No"
    },
    "Version Number": {
        "name": "Version Number",
        "data_type": "Text",
        "definition": "C181232\nFor review purpose, see definition of the controlled terminology below:\nA string of numerals that uniquely identifies a specific version of a study protocol.",
        "guidance": " use by the Sponsor at their discretion.",
        "conformance": "Optional ",
        "cardinality": "One to one, Protocol Identifier",
        "relationship": "Title Page",
        "value": "Number",
        "business_rules": "Value Allowed: Yes\nRelationship: , Protocol Identifier\nConcept: C181232",
        "repeating": "No"
    },
    "Version Date": {
        "name": "Version Date",
        "data_type": "Date",
        "definition": "C93813\nFor review purpose, see definition of the controlled terminology below\nThe date on which the document is versioned.",
        "guidance": "or use by the Sponsor at their discretion.",
        "conformance": "Optional ",
        "cardinality": "One to one; one to Version Number",
        "relationship": "Title page",
        "value": "Date Format ",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: C93813",
        "repeating": "No"
    },
    "Amendment Identifier": {
        "name": "Amendment Identifier",
        "data_type": "Text or \u201cOriginal Protocol\u201d",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identif a protocol amendment.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "12.3",
        "value": "Text or \u201cOriginal Protocol\u201d ",
        "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading \u201cDocument\u201d\nConcept: CNEW",
        "repeating": "Yes, reuse from the title page"
    },
    "": {
        "name": "",
        "data_type": "Number",
        "definition": "N/A",
        "guidance": "Add criteria as needed.  the criteria sequentially",
        "conformance": "Required",
        "cardinality": "One to many",
        "relationship": "5.3",
        "value": "# is an identifier <criterion identifier> unique number and not replaceable",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.3 Exclusion Criteria\nConcept: Sequential number",
        "repeating": "Yes. number consecutively, repeatable for each exclusion criteria, if deleted do not replace, do not duplicate"
    },
    "Nonproprietary Names": {
        "name": "Nonproprietary Names",
        "data_type": "Text",
        "definition": "C97054\nFor review purpose, see definition of the controlled terminology below\nDrug name that is not protected by a trademark, usually descriptive of its chemical structure. ",
        "guidance": "Omit nonproprietary name fields if a nonproprietary name has not yet been assigned.",
        "conformance": "Optional; Blank ",
        "cardinality": "One to many; Many to ; Many to Protocol Identifier",
        "relationship": "Title Page",
        "value": "Text for example WHO INN, USAN, JAN, XEVMPD",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: C97054",
        "repeating": "Yes, repeatable for each nonproprietary name \n"
    },
    "Proprietary Names": {
        "name": "Proprietary Names",
        "data_type": "Text",
        "definition": "C71898\nFor review purpose, see definition of the controlled terminology below\nA commercial name granted by a naming authority for use in marketing an experimental intervention.",
        "guidance": "Omit proprietary name fields if not yet established.",
        "conformance": "Optional; Blank",
        "cardinality": "One to many; Many to ; Many to Protocol Identifier",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier; \nConcept: C71898",
        "repeating": "Yes, repeatable for each proprietary name"
    },
    "Trial Short Title": {
        "name": "Trial Short Title",
        "data_type": "Text",
        "definition": "C132345\nFor review purpose, see definition of the controlled terminology below\nThe short descriptive name for the protocol.",
        "guidance": "Short title should convey in plain language what the trial is about and should be suitable for use as \u201cBrief Title\u201d or \u201cTitle in Plain Language\u201d in global clinical trial registries. It can also be suitable for use with informed consents and ethics committee submissions.",
        "conformance": "Optional",
        "cardinality": "One to one, One to Protocol identifier",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: C132345",
        "repeating": "No"
    },
    "Sponsor Name": {
        "name": "Sponsor Name",
        "data_type": "Text",
        "definition": "C70793\nFor review purpose, see definition of the controlled terminology below\nAn individual, company, institution, or organisation that takes responsibility for the initiation, management, and/or financing of a clinical study. [After ICH E6, WHO, 21 CFR 50.3 (e), and after IDMP]",
        "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
        "conformance": "Required ",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: C70793",
        "repeating": "No"
    },
    "Sponsor Legal Address": {
        "name": "Sponsor Legal Address",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial Sponsor.",
        "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
        "conformance": "Required ",
        "cardinality": "One to one, One to Sponsor Name",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name\nConcept: CNEW",
        "repeating": "No"
    },
    "CoSponsor Name": {
        "name": "CoSponsor Name",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the trial co-Sponsor.",
        "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field.",
        "conformance": "Optional ",
        "cardinality": "One to one, One to Sponsor Name, One to Protocol Identifier",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name, Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "CoSponsor Legal Address": {
        "name": "CoSponsor Legal Address",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the trial co-sponsor.",
        "guidance": "Provide the legal name of the individual or pharmaceutical or medical device company, governmental agency, academic institution, private organisation, or other organisation who takes primary responsibility for and initiates a clinical investigation. If more than one Sponsor, list the Primary Sponsor in this field\n",
        "conformance": "Optional ",
        "cardinality": "One to one; One to Heading; One to Co-Sponsor Name",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Co- Sponsor Name\nConcept: CNEW",
        "repeating": "No"
    },
    "Local Sponsor Name": {
        "name": "Local Sponsor Name",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
        "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Sponsor Name and Address Field.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Sponsor Name and Address; Many to Sponsor Name",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Sponsor Name and Address; Sponsor Name; Country\nConcept: CNEW",
        "repeating": "Yes, repeatable for each Local Sponsor Name"
    },
    "Local Sponsor Address": {
        "name": "Local Sponsor Address",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the sponsor's legal representative at a geographical region within which the sponsor has no legal presence.",
        "guidance": "In some countries, the clinical trial Sponsor may be the local affiliate company (or designee). In such cases, indicate this in the Sponsor Local Name and Address Field.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Local Sponsor; One to Country ",
        "relationship": "Title page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Local Sponsor, Country\nConcept: CNEW",
        "repeating": "No"
    },
    "Device Manufacturer Name": {
        "name": "Device Manufacturer Name",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe organisation defined as being responsible for creating the device as stated on the package in which the product is supplied.",
        "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier; One to Sponsor Name",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier; Sponsor Name\nConcept: CNEW",
        "repeating": "Yes, repeatable for each device manufacturers"
    },
    "Device Manufacturer Address": {
        "name": "Device Manufacturer Address",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe legally registered address of the device manufacturer.",
        "guidance": "Manufacturer name and address information is required only for protocols that include investigational device(s) and should not be included for other protocols. Include the manufacturer address only if the manufacturer is different than the Sponsor listed above.\nAdd additional fields as needed if multiple investigational devices will be used in the trial. Delete this line if not applicable.",
        "conformance": "Optional",
        "cardinality": "One to One; One to Device Manufacturer Name",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Device Manufacturing Name\nConcept: CNEW",
        "repeating": "No"
    },
    "EU CT Number": {
        "name": "EU CT Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Clinical Trials Information System (CTIS) of the European Medicines Agency.",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes; EU CT number: yyyy-5xxxxx-xx with YYYY corresponding to a year i.e. 2024 and x being an integer\nRelationship: Heading; Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "IDE Number": {
        "name": "IDE Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational Device Exemption (IDE) application, as assigned by the US Food and Drug Administration.",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "jRCT Number": {
        "name": "jRCT Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the Japan Registry for Clinical Trials (JRCT) of the Ministry of Health, Labour and Welfare (MHLW) in Japan.",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "NCT Number": {
        "name": "NCT Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the protocol registration and results (PRS) system of the US National Library of Medicine.",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW ",
        "repeating": "No"
    },
    "NMPA IND Number": {
        "name": "NMPA IND Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial under an Investigational New Drug (IND) application, as assigned by the Chinese National Medicinal Products Administration (NMPA).",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to rotocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading; Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "WHOUTN Number": {
        "name": "WHOUTN Number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to identify a clinical trial, as assigned by the World Health Organisation's International Clinical Trial's Registry Platform (ICTRP).",
        "guidance": "Include all numbers that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for numbers not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "UTN/WHO: Uxxxx-xxxx-xxxx with X being an integer",
        "business_rules": "Value Allowed: Yes; \nRelationship: Heading; Protocol Identifier; \nConcept: CNEW",
        "repeating": "No"
    },
    "Other Regulatory Identifier": {
        "name": "Other Regulatory Identifier",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below \nA sequence of characters used to identify a clinical trial, that is different than the one(s) previously specified or mentioned.",
        "guidance": "Include all that are applicable for the trial and available at the time of protocol or amendment finalisation. Delete prompts for not available at the time of document finalisation. Delete unused fields. Add fields for \u201cother\u201d if more than one is needed.",
        "conformance": "Optional",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Protocol Identifier\nConcept: CNEW",
        "repeating": "Yes, repeatable for each regulatory agency identifier"
    },
    "Describe Method": {
        "name": "Describe Method",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe narrative text describing the technique used to approve the protocol.",
        "guidance": "Include either the Sponsor signature or the statement below.",
        "conformance": "Conditional if Sponsor Protocol Approval Statement",
        "cardinality": "One to Sponsor Protocol Approval Statement",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Sponsor Protocol Approval Statement\nConcept: CNEW",
        "repeating": "No"
    },
    "contact information for Medical Expert as designated by sponsor or state location where information can be found": {
        "name": "contact information for Medical Expert as designated by sponsor or state location where information can be found",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe contact information for the sponsor's representative who can advise on specific trial-related medical questions or problems.",
        "guidance": "N/A",
        "conformance": "",
        "cardinality": "One to one; One to Protocol Identifier",
        "relationship": "Title Page",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Medical Expert Contact Response\nConcept: CNEW",
        "repeating": "No"
    },
    "The table below describes the current amendment": {
        "name": "The table below describes the current amendment",
        "data_type": "Text",
        "definition": "N/A",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "Amendment Details",
        "value": "",
        "business_rules": "Value Allowed: No\nRelationship: Current Amendment\nConcept: Required text",
        "repeating": "No"
    },
    "Approximately  enrolled GloballyLocallyby Cohort": {
        "name": "Approximately  enrolled GloballyLocallyby Cohort",
        "data_type": "Text",
        "definition": "C68846\nCNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
        "guidance": "",
        "conformance": "Optional",
        "cardinality": "One to one; One to amendment number",
        "relationship": "Amendment Details",
        "value": "Approximate <#/%> enrolled <Globally/Locally/by Cohort>",
        "business_rules": "Value Allowed: Yes\nRelationship: Statement\nConcept: C68846, CNEW",
        "repeating": "Yes, reuse to Section 12.3 "
    },
    "Number or ": {
        "name": "Number or ",
        "data_type": "Number",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
        "guidance": "",
        "conformance": " if Original Protocol =No",
        "cardinality": "One to Amendment Number",
        "relationship": "Amendment Details",
        "value": "Integer for Number or one decimal point for percent",
        "business_rules": "Value Allowed: Yes\nRelationship: Table Row Heading, Statement\nConcept: CNEW",
        "repeating": "Yes, reuse to section 12.3"
    },
    "Other description": {
        "name": "Other description",
        "data_type": "Text",
        "definition": "C17649\nFor review purpose, see definition of the controlled terminology below\nDifferent than the one(s) previously specified or mentioned. ",
        "guidance": "Choose from the available categories as the primary reason and secondary reason(s) for the amendment. Select the closest match among the choices. Changes to primary estimand, endpoints, or related measures should be listed as a change of strategy. If none of the choices apply, choose \u201cother\u201d and provide a description. If no secondary reason, indicate \u201cnot applicable\u201d for the secondary reason.",
        "conformance": "Conditionalif Other is selected as a Valid Value",
        "cardinality": "One to one",
        "relationship": "Amendment Details",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Heading, Secondary reason, Protocol Identifier, Protocol Amendment\nConcept:C17649",
        "repeating": "No"
    },
    "Amendment Summary": {
        "name": "Amendment Summary",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short narrative representation describing the changes introduced in the current version of the protocol.",
        "guidance": "Describe key changes briefly. Changes which are included in the amendment but unrelated to the key changes do not need to be described here. ",
        "conformance": "Conditional: if there is an amendment",
        "cardinality": "One to Amendment identifier",
        "relationship": "Amendment Details",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details; Amendment Identifier, Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "If yes briefly explain": {
        "name": "If yes briefly explain",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA short descriptive account of any substantial impacts on the reliability and robustness of the data generated in the clinical trial due to the protocol amendment.",
        "guidance": "Briefly Explain Substantial Impact on Data",
        "conformance": "Conditional: if there is an amendment and if the answer to \"Is this amendment likely to have a substantial impact on the reliability and robustness of the data generated in the clinical trial?\" is yes",
        "cardinality": "One to amendment identifier",
        "relationship": "Amendment Details",
        "value": "",
        "business_rules": "Value Allowed: Yes\nRelationship: Amendment Details, Amendment Identifier, Protocol Identifier\nWhen the value is yes there is a text response for explanation\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Change": {
        "name": "Description of Change",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the change introduced in the current version of the protocol.",
        "guidance": "N/A",
        "conformance": "Conditional:  ",
        "cardinality": "Column Heading \nRow Content",
        "relationship": "12.3",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading and 12.3 Prior Protocol Amendment(s)\nConcept: CNEW",
        "repeating": "Yes, repeatable for every description of change"
    },
    "Brief Rationale for Change": {
        "name": "Brief Rationale for Change",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe brief reason for the change introduced in the current version of the protocol.",
        "guidance": "N/A",
        "conformance": "Conditional: ",
        "cardinality": "One to Column Heading\nRow description of change \nSection# and Name",
        "relationship": "12.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Table Column Heading Brief Rationale for Change and <Description of Change>\nConcept: CNEW",
        "repeating": "Yes, repeatable for every description of change"
    },
    "Table of Contents": {
        "name": "Table of Contents",
        "data_type": "Word Generated Table of Contents",
        "definition": "N/A",
        "guidance": "N/A",
        "conformance": "Generated",
        "cardinality": "N/A",
        "relationship": "Table of Contents",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: N/A\nConcept: N/A",
        "repeating": "No"
    },
    "Primary and Secondary Objectives and Estimands": {
        "name": "Primary and Secondary Objectives and Estimands",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA descriptive summary of the primary and secondary objectives and their associated estimands related to the trial.",
        "guidance": "Summarise the primary and secondary objectives and any associated estimands in natural, nontechnical (layperson) language. \nFor trials intended to estimate a treatment effect or test a hypothesis related to a treatment effect, include the primary and secondary objectives and any associated estimands using a nontechnical summary describing the objective and treatment effect of interest (estimand). \nFor other types of trials not intended to estimate a treatment effect or test a hypothesis related to a treatment effect, define trial objectives and describe additional information relevant to the clinical question(s) of interest (e.g., the endpoint(s) associated with each objective).\nFor trials with numerous objectives in which the description of objectives will exceed half a page, consider including the most important objectives and estimands in the synopsis and refer to Section 3 Trial Objectives and Associated Estimands, which covers the objectives and estimands in technical detail. For considerations on estimands, refer to ICH E9(R1).",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "1.1.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 1.1.1 Primary and Secondary Objectives and Estimands\nConcept: CNEW",
        "repeating": "Yes, Reuse <Primary Objective> and <Endpoint> for each Primary Objective from section 3.1, reuse <Secondary Objective and <ndpoint> for each Secondary Objective from section 3.2."
    },
    "Nonproprietary name or INN or Enter Not applicable": {
        "name": "Nonproprietary name or INN or Enter Not applicable",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the comparator against which the study intervention is evaluated.",
        "guidance": "",
        "conformance": "Conditional: if there is a nonproprietary name or INN",
        "cardinality": "One to many",
        "relationship": "1.1.2",
        "value": "[Nonproprietary name] or [INN] or <Enter \u201cN/A\u201d>",
        "business_rules": "Value Allowed: Yes\nRelationship: Row title; Protocol Identifier\nConcept: CNEW",
        "repeating": "No"
    },
    "Not applicable": {
        "name": "Not applicable",
        "data_type": "Text",
        "definition": "Verbatim Text",
        "guidance": "",
        "conformance": "Conditional: if there is no nonproprietary name and INN",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "N/A",
        "business_rules": "Value Allowed: Yes, cannot have not applicable if Nonproprietary or INN are completed\nRelationship: Row title; Control Description; Protocol Identifier\nConcept: Verbatim Text",
        "repeating": "No"
    },
    " ": {
        "name": " ",
        "data_type": "Number",
        "definition": "C49694\nFor review purpose, see definition of the controlled terminology below\nThe anticipated maximum age of the participants to be entered in a clinical trial",
        "guidance": "Population age range - For trials in which multiple age ranges may be eligible (for example, a younger cohort and an older cohort), indicate the minimum and maximum ages for the trial overall, with an additional comment for any excluded age ranges.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Integer",
        "business_rules": "Value Allowed: Yes\nRelationship: population age, Maximum Age; Maximum unit of age\nConcept:C49694",
        "repeating": "No"
    },
    "Number of Arms": {
        "name": "Number of Arms",
        "data_type": "Number",
        "definition": "C98771\nFor review purpose, see definition of the controlled terminology below\nThe planned number of intervention groups.",
        "guidance": "Enter the numeric value for the number of arms in the trial. For trials with a different number of arms in different periods, populate this field based on the period with the greatest number of arms.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Integer",
        "business_rules": "Value Allowed: Yes\nRelationship: Number of Arms, Heading; Protocol Identifier\nConcept: C98771",
        "repeating": "No"
    },
    "Number of Participants": {
        "name": "Number of Participants",
        "data_type": "Number",
        "definition": "C49692\nFor review purpose, see definition of the controlled terminology below\nThe planned number of participant be entered in a clinical trial.",
        "guidance": "State the expected number of participants to be assigned to trial intervention/enrolled. Indicate whether the number provided is the target or maximum number of individuals to be randomly assigned to trial intervention/enrolled",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Integer; <Number of Participants> participants will be",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: C49692",
        "repeating": "No"
    },
    "alternate description of planned duration of trial intervention if duration will vary": {
        "name": "alternate description of planned duration of trial intervention if duration will vary",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative textual narrative for the planned duration of trial intervention.",
        "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
        "conformance": "Conditional: when an alternate description for planned duration of trial Intervention if the duration varies",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "text",
        "business_rules": "Value Allowed: Yes\nRelationship: Total duration of trial intervention for each participant:\nConcept: CNEW",
        "repeating": "No"
    },
    "alternate description of planned duration of trial participation if duration will vary": {
        "name": "alternate description of planned duration of trial participation if duration will vary",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn alternative narrative for the planned duration of trial participation.",
        "guidance": "Select one of the two options for total planned duration of trial intervention and trial participation for each participant. Note that the total duration of trial participation should include any washout and any follow-up periods in which the participant is not receiving trial intervention. When duration will vary, provide a short explanation (e.g., \u201cevent-driven\u201d or \u201cadaptive design\u201d",
        "conformance": "Conditional: when an alternate description for planned duration of trial participation if duration will vary",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Total duration of planned duration of trial participation if duration will vary:\nConcept: CNEW",
        "repeating": "No"
    },
    "Additional Description of Duration": {
        "name": "Additional Description of Duration",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative clarifying information regarding the length of time an individual usage of trial intervention or planned time in a trial.",
        "guidance": "If necessary, include any clarifications or cross-references to details in the main body of the protocol in the optional field below.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Duration\nConcept: CNEW",
        "repeating": "No"
    },
    "Other Committees": {
        "name": "Other Committees",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA committee that is different than the one(s) previously specified or mentioned.",
        "guidance": "Delete \u201cOther Committees\u201d if not applicable.",
        "conformance": "Optional ",
        "cardinality": "One to one",
        "relationship": "1.1.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Other Committees\nConcept: CNEW",
        "repeating": "No"
    },
    "Trial Schema": {
        "name": "Trial Schema",
        "data_type": "Image; Text",
        "definition": "C93682\nFor review purpose, see definition of the controlled terminology below\nA diagram that outlines the decision points (e.g. randomisation, response evaluation) that define the different paths a participant could take through the trial.",
        "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "1.2",
        "value": "Image; Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: C93682",
        "repeating": "Yes, repeatable within Section"
    },
    "Schema Notes": {
        "name": "Schema Notes",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA brief written record describing the trial schematic.",
        "guidance": "The purpose of this section is to provide a visual depiction of the trial design, orienting users of the protocol to the key features of the design. The schema depicts the trial arms, the flow of individual participants through the progression of trial period(s)/epochs (such as screening, washout/run-in, intervention, and key milestones [e.g., randomisation, cross-over, end of treatment, end of study, post-treatment follow-up]). For complex trials, additional schemas may be added to describe activities or trial periods in greater detail.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "1.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 1.2 Trial Schema\nConcept: CNEW",
        "repeating": "Yes, repeatable and aligned with appropriate schema"
    },
    "Schedule of Activities": {
        "name": "Schedule of Activities",
        "data_type": "Table; Text; Image",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA standardised representation of planned clinical trial activities including interventions (e.g. administering drug, surgery) and study administrative activities (e.g. obtaining informed consent, distributing clinical trial material and diaries, randomisation) as well as assessments.",
        "guidance": "The schedule of activities must capture the procedures that will be accomplished at each trial visit, and all contact with participants, e.g., telephone contacts. This includes any tests that are used for eligibility, participant randomisation or stratification, or decisions on trial intervention discontinuation. Allowable windows should be stated for all visits and procedures. A tabular format is recommended.\nWhen applicable for studies with extensive sampling, e.g., serial PK sampling, a separate table may be added",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "1.3",
        "value": "Table; text; Image",
        "business_rules": "Value Allowed: Yes\nRelationship: 1.3 Schedule of Activities\nConcept: CNEW",
        "repeating": "Yes, repeatable for each Schedule of Activity if needed"
    },
    "Purpose of Trial": {
        "name": "Purpose of Trial",
        "data_type": "Text",
        "definition": "C146997\nFor review purpose, see definition of the controlled terminology below\nThe overall rationale, reason, or intention of the clinical trial.",
        "guidance": "Explain why the trial is needed, why the research questions being asked are important. Do not restate the objectives or estimands. Do not restate the IB; rather, cross reference to the IB as applicable to the description. ",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "2.1 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 2.1 Purpose of Trial\nConcept: C146997",
        "repeating": "No"
    },
    "Trialspecific Intervention Risks and Mitigations": {
        "name": "Trialspecific Intervention Risks and Mitigations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial interventions and mitigation strategies to be employed within the trial.",
        "guidance": "Trial Intervention \u2013 Describe risks related to trial-specific treatments and interventions. For the protocol, focus on the relevant key risks for THIS trial. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "2.2.",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
        "repeating": "No"
    },
    "Trialspecific Procedure Risks and Mitigations": {
        "name": "Trialspecific Procedure Risks and Mitigations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with the trial procedures and mitigation strategies to be employed within the trial.",
        "guidance": "Trial Procedures \u2013 risks associated with the design (, placebo arm) and procedures specific to  trial (, biopsies), and any measures to control or mitigate the risks. Provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section. This is not intended to be an exhaustive list of all possible risks associated with trial procedures but should focus on the unique risks inherent in the design or less common or high-risk procedures. As above, provide a brief description of strategies to mitigate identified risks or provide a cross-reference to the relevant protocol section.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "2.2. ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
        "repeating": "No"
    },
    "Trialspecific Other Risks and Mitigations": {
        "name": "Trialspecific Other Risks and Mitigations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the potential risks associated with other trial-related agents and mitigation strategies to be employed within the trial.",
        "guidance": "Other \u2013 Consider risks associated with other items (, challenge agents, imaging agents, medical devices). This could include discussion of risk mitigation for special populations, if not described elsewhere. Insert a line for each, as needed.",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "2.2.",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 2.2. Risk Summary and Mitigation Strategy\nConcept: CNEW",
        "repeating": "No"
    },
    "Primary Objective": {
        "name": "Primary Objective",
        "data_type": "Text",
        "definition": "C85826\nFor review purpose, see definition of the controlled terminology below\nThe principle reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
        "guidance": "N/A",
        "conformance": "Required",
        "cardinality": "One to One, One to T Number 3.1.X, One to Estimand Characteristics Table, Primary Objective X, Protocol Identifier ",
        "relationship": "3.1.X",
        "value": "",
        "business_rules": "Value Allowed: Yes\nRelationship: 3.1.X Primary Objective \nConcept: C85826",
        "repeating": "\n"
    },
    " Table of Estimand Characteristics including Endpoint at a minimum": {
        "name": " Table of Estimand Characteristics including Endpoint at a minimum",
        "data_type": "Text",
        "definition": "N/A",
        "guidance": "N/A",
        "conformance": " ",
        "cardinality": "One to one",
        "relationship": "3.1.X",
        "value": "Estimand Characteristics",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: Heading",
        "repeating": "\n\n"
    },
    "Population": {
        "name": "Population",
        "data_type": "Text",
        "definition": "C70833\nFor review purpose, see definition of the controlled terminology below\nThe population of patients targeted by the clinical question. This will be represented by the entire trial population, a subgroup defined by a particular characteristic measured at baseline, or a principal stratum defined by the occurrence (or non-occurrence, depending on context) of a specific intercurrent event.",
        "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
        "conformance": "Conditional: If there is a population",
        "cardinality": "One to Row Heading, One to Exploratory Objective Table, Exploratory Objective X, Protocol Identifier ",
        "relationship": "3.3.X ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C70833",
        "repeating": "\n"
    },
    "Treatment": {
        "name": "Treatment",
        "data_type": "Text",
        "definition": "C49236\nFor review purpose, see definition of the controlled terminology below\nThe treatment condition of interest and, as appropriate, the alternative treatment condition to which comparison will be made (referred to as \u201ctreatment\u201d through the remainder of this document). These might be individual interventions, combinations of interventions administered concurrently, e.g. as add-on to standard of care, or might consist of an overall regimen involving a complex sequence of interventions.",
        "guidance": "List of key aspects of treatment regimens in each study group, including at least investigational agents, dosage, and administration route",
        "conformance": "Conditional: If there is a ",
        "cardinality": "One to Row Heading, One Exploratory Objective Table, Project Identifier ",
        "relationship": "3.3.X ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand; Protocol Identifier\nConcept: C49236",
        "repeating": "\n"
    },
    "PopulationLevel Summary": {
        "name": "PopulationLevel Summary",
        "data_type": "Text",
        "definition": "C188853\nFor review purpose, see definition of the controlled terminology below\n A synopsis of the clinical endpoint of interest within the analysis target study population.",
        "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
        "conformance": "Conditional: If there is a ",
        "cardinality": "One to Row Heading, One Exploratory Objective Table, Project Identifier ",
        "relationship": "3.3.X ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C188857",
        "repeating": "\n"
    },
    "Description of Intercurrent Event": {
        "name": "Description of Intercurrent Event",
        "data_type": "Text",
        "definition": "\nC188853\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
        "guidance": "Enter Description of Intercurrent Event",
        "conformance": "",
        "cardinality": "One to one or as many intercurrent event as available ",
        "relationship": "3.3.X",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Estimand Characteristics\nConcept: C188853",
        "repeating": "Yes, repeatable for each intercurrent event"
    },
    "Intercurrent Event Strategy": {
        "name": "Intercurrent Event Strategy",
        "data_type": "Text",
        "definition": "C188857\nFor review purpose, see definition of the controlled terminology below\nA textual description of the planned strategy to address intercurrent events.",
        "guidance": "Description of the strategy to address the intercurrent event (e.g. a treatment policy strategy); cross-reference the justification in Section 4. If there is >1 intercurrent event for an objective, add additional intercurrent event rows",
        "conformance": "",
        "cardinality": "One to one ",
        "relationship": "3.3.X",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading Strategy, Description\nConcept: C188857",
        "repeating": "Yes, repeatable for each intercurrent event"
    },
    "Secondary Objective": {
        "name": "Secondary Objective",
        "data_type": "Text",
        "definition": "C85827\nFor review purpose, see definition of the controlled terminology below\nThe secondary reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
        "guidance": "N/A",
        "conformance": "Required",
        "cardinality": "One to one; T Number 3.2.X, One to Estimand  Table, Secondary Objective X, Protocol Identifier ",
        "relationship": "3.2.X ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 3.2.X Secondary Objective, Estimand Characteristics table\nConcept: C85827",
        "repeating": "\n"
    },
    "If a Secondary Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum": {
        "name": "If a Secondary Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum",
        "data_type": "Text",
        "definition": "N/A",
        "guidance": "{If a Secondary Objective has been entered: <Enter Table of Estimand Characteristics>} including Endpoint at a minimum}",
        "conformance": "Conditional: either Enter Table of Estimand Characteristics or details of the characteristics relevant to objective",
        "cardinality": "One to many rows",
        "relationship": "3.2.X",
        "value": "Estimand Characteristics",
        "business_rules": "Value Allowed: No\nRelationship: 3 3.2 Secondary Objective(s) and associated Estimand(s)\nConcept: Heading",
        "repeating": "\n\n"
    },
    "Exploratory Objective": {
        "name": "Exploratory Objective",
        "data_type": "Text",
        "definition": "C163559\nFor review purpose, see definition of the controlled terminology below\nThe exploratory reason for performing a study in terms of the scientific questions to be answered by the analysis of data collected during the study.",
        "guidance": "State each exploratory objective. This should generally include documentation of associated exploratory endpoints. It may be helpful in some cases to describe precise estimands to provide clarity on what is being estimated.",
        "conformance": "Conditional: an exploratory objective is part of the trial",
        "cardinality": "One to T Number 3.3.X, One to Estimand Characteristic Table, Exploratory Objective X, Protocol Identifier ",
        "relationship": "3.3.X ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 3.3.X Exploratory Objective(s)\nConcept: C163559",
        "repeating": "\n"
    },
    "If an Exploratory Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum": {
        "name": "If an Exploratory Objective has been entered Enter Table of Estimand Characteristics including Endpoint at a minimum",
        "data_type": "Text",
        "definition": "N/A",
        "guidance": "{If an Exploratory Objective has been entered: <Table of Estimand Characteristics> including Endpoint at a minimum}",
        "conformance": "Conditional: either Enter Table of Estimand Characteristics or details of the characteristics relevant to objective",
        "cardinality": "One to many",
        "relationship": "3.3.X",
        "value": "",
        "business_rules": "Value Allowed: Yes\nRelationship: 3.3.3 Exploratory Objective(s) and associated Estimand(s);Table column Heading; Description, Population, Treatment, Endpoint, Population-Level, Intercurrent Event (1\u2026n)\nConcept: Heading",
        "repeating": "\n"
    },
    "Endpoint": {
        "name": "Endpoint",
        "data_type": "Text",
        "definition": "C25212\nFor review purpose, see definition of the controlled terminology below\nThe variable to be obtained for each patient that is required to address the clinical question. The specification of the variable might include whether the patient experiences an intercurrent event",
        "guidance": "List of key characteristics, such as demographic characteristics (e.g. age, sex) and clinical characteristics (e.g. prior therapies, symptoms, severity, biomarker status)",
        "conformance": "",
        "cardinality": "One to Row Heading, One to Exploratory Objective Table, Project Identifier ",
        "relationship": "3.3.X",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Row Heading, Description; Table Estimand Characteristics, Exploratory (1\u2026n) Estimand\nConcept: C25212",
        "repeating": "\n"
    },
    "Description of Trial ": {
        "name": "Description of Trial ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the trial duration.",
        "guidance": "Describe the overall trial design and intervention model (e.g., single group, parallel group, cross-over, factorial, sequential), the expected number of participants, and the control method (e.g., placebo, active comparator, low dose, external, standard of care, sham procedure, or none [uncontrolled]). If there are any key aspects of the investigational trial intervention that inform the selection of the intervention model, this should be described.\nIf applicable, indicate other design characteristics (e.g., superiority, noninferiority, dose escalation, or equivalence).\nIf the trial will have an adaptive or novel design (e.g., the trial will be conducted under a master protocol), provide a summary of these design aspects.\nIf applicable, describe within-trial transition rules, e.g., transitions involving cohorts or trial parts. Dose escalation or dose-ranging details should also be described.",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "4.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
        "repeating": "No"
    },
    "Method of Assignment to Trial Intervention": {
        "name": "Method of Assignment to Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial intervention or trial arm.",
        "guidance": "State the method of assignment to trial intervention the level and method of blinding that will be used with reference to Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding.\n",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "4.1 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Level of Blinding": {
        "name": "Description of Level of Blinding",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the level of awareness of the study participants and/or personnel to the respective intervention(s) or assessments being observed, received or administered",
        "guidance": "N/A",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "4.1 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
        "repeating": "No"
    },
    "Additional Description of Trial Design": {
        "name": "Additional Description of Trial Design",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn extra or further textual representation of the trial design.",
        "guidance": "",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "4.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.1 Description of Trial Design\n\nConcept: CNEW",
        "repeating": "No"
    },
    "Stakeholder Input into Design": {
        "name": "Stakeholder Input into Design",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe textual representation of the way in which trial stakeholders were consulted when determining the trial design.",
        "guidance": "If applicable, describe any stakeholder (e.g., patient, healthcare professional and patient advocacy groups) involvement in the design of the trial and any suggestions implemented",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "4.1.1 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.1.1 Stakeholder Input into Design\nConcept: CNEW",
        "repeating": "No"
    },
    "Overall Rationale for Trial Design": {
        "name": "Overall Rationale for Trial Design",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial design considerations that are different than the one(s) previously specified or mentioned.",
        "guidance": "N/A",
        "conformance": "Conditional: If Level 3 subheadings are not used",
        "cardinality": "One to one",
        "relationship": "4.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.2 Rationale for Trial Design\nConcept: CNEW",
        "repeating": "No"
    },
    "Rationale for Trial Intervention Model": {
        "name": "Rationale for Trial Intervention Model",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for why the intervention model was chosen for the trial.",
        "guidance": "Provide a rationale for the trial intervention model described in Section 4.1 Description of Trial Design with a cross-reference to Section 6.2 Rationale for Investigational Intervention Dose and Regimen. Rationale for choice of comparator, if applicable, should be described separately in Section 4.2.5 Rationale for Control Type. A rationale for the choice of trial population should be described separately in Section 5.1 Description of Trial Population and Rationale.\n",
        "conformance": "Conditional: when  is not used",
        "cardinality": "One to one",
        "relationship": "4.2.",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.2.Rational for Intervention Model\nConcept: CNEW",
        "repeating": "No"
    },
    "Rationale for Duration": {
        "name": "Rationale for Duration",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the trial duration.",
        "guidance": "Provide a rationale that the trial duration is appropriate for a reliable and relevant evaluation of the trial intervention per the trial objective(s).",
        "conformance": "Conditional: when  is not used",
        "cardinality": "One to one",
        "relationship": "4.2.",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.2. Rationale for Duration\nConcept: CNEW",
        "repeating": "No"
    },
    "Rationale for Interim Analysis": {
        "name": "Rationale for Interim Analysis",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation for the analysis comparing intervention groups at any time before the formal completion of the trial, usually before recruitment is complete.",
        "guidance": "If applicable, provide a rationale for any interim analysis planned with respect to its purpose (e.g., stopping the trial early for efficacy or futility) and timing.",
        "conformance": "Conditional: when is not used",
        "cardinality": "One to one",
        "relationship": "4.2.",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.2.Rational for Interim Analysis\nConcept: CNEW",
        "repeating": "No"
    },
    "Rationale for Other Trial Design Aspects": {
        "name": "Rationale for Other Trial Design Aspects",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for additional trial design considerations that are different than the one(s) previously specified or mentioned.",
        "guidance": "Discuss rationale for any additional aspects of the design not addressed above.",
        "conformance": "Conditional: when  is not used ",
        "cardinality": "One to one",
        "relationship": "4.2.7 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.2.7 Rational for Other Trial Design Aspects\nConcept: CNEW",
        "repeating": "No"
    },
    "Trial Stopping Rules": {
        "name": "Trial Stopping Rules",
        "data_type": "Text",
        "definition": "C142698\nFor review purpose, see definition of the controlled terminology below \nA criterion that, when met by the accumulating data, indicates that the trial can or should be stopped early to avoid putting participants at risk unnecessarily or because the intervention effect is so great that further data collection is unnecessary.",
        "guidance": "If applicable, describe any trial-specific stopping rules, including guidance on when the trial should be stopped for efficacy or safety reasons, when a cohort or dose escalation should be terminated, and/or when a given treatment arm should be terminated. If applicable, describe any rules that may result in a temporary pause of dosing and/or enrollment into the trial and criteria for restarting enrollment. Ensure that the trial stopping rules are aligned with the specifications that are described in Section 10.9 for Interim Analyses.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "4.3 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.3 Trial Stopping Rules\nConcept: C142698",
        "repeating": "No"
    },
    "Start of Trial": {
        "name": "Start of Trial",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial start.",
        "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). Consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.1 Early Site Closure.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "4.4 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial and End of Tria\nConcept: CNEW",
        "repeating": "No"
    },
    "End of Trial": {
        "name": "End of Trial",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description containing a concise explanation, any local regulatory requirements and considerations, extensions, follow-up, and analysis for the trial end.",
        "guidance": "Define key timepoints in the trial, including trial start and end definitions. (e.g., a key timepoint definition for start of trial might be when the informed consent is signed by the first participant and a key timepoint definition for end of trial might be when participants are no longer being examined or the last participant\u2019s last trial assessment has occurred). If applicable, consider local regulatory requirements for these and other definitions (e.g., the first act of recruitment).\nIf appropriate, provide a cross-reference to Section 11.10 Early Site Closure.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "4.4 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.4 Start of Trial\nConcept: CNEW",
        "repeating": "No"
    },
    "Access to Trial Intervention after End of Trial": {
        "name": "Access to Trial Intervention after End of Trial",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual representation containing information about whether and how trial participants have access to the trial interventions after the trial ends.",
        "guidance": "If applicable, describe any possibilities for access to trial intervention, if any, beyond completion of the trial. Planned extension trials, if described in Section 4.1 Description of Trial Design do not need to be repeated.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "4.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 4.5 Access to Trial Intervention After End of Trial\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Trial Population and Rationale": {
        "name": "Description of Trial Population and Rationale",
        "data_type": "Text",
        "definition": "CNEW\nA narrative representation of the rationale for selection of trial population describing how the selected population can meet the trial objectives and how the enrolment criteria reflect the targeted populations.",
        "guidance": "Describe the population selected (e.g., healthy participants, adult participants, paediatric participants) and how the enrollment criteria reflect the populations that are likely to use the drug if approved. Specify the population age range (e.g., \u22643 months, \u226518 to \u226480 years old) including the time point at which qualification for age criteria is determined (e.g., at time of screening vs randomisation for paediatric trials). Specify any key diagnostic criteria for the population (e.g., \u201cacute lung injury\u201d, or a specific biomarker profile). If applicable, describe similar conditions or diseases and their differential diagnosis. \nProvide a rationale for the trial population ensuring that the population selected is well defined and clinically recognisable. Describe how the selected population can meet the trial objectives and how the enrollment criteria reflect the population of interest.\nIf the population targeted by a clinical question is based on a subset of the entire trial population, e.g. defined by a particular characteristic measured at baseline (e.g. a specific biomarker), this subset should be justified in this section.\nJustify whether the trial intervention is to be evaluated in paediatric participants, in adults unable to consent for themselves, other vulnerable participant populations, or those that may respond to the trial intervention differently (e.g., elderly, hepatic or renally impaired, or immunocompromised participants). ",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.1 Description of Trial Population and Rationale\nConcept: CNEW",
        "repeating": "No"
    },
    "Inclusion Criterion": {
        "name": "Inclusion Criterion",
        "data_type": "Text",
        "definition": "C25532 \nFor review purpose, see definition of the controlled terminology below\nThe criteria in a protocol that prospective subjects must meet to be eligible for participation in a study.",
        "guidance": "Add criteria as needed. sequentially",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: to Number # 5.2 Inclusion Criteria\nConcept: C25532",
        "repeating": "umber consecutively, repeat for each inclusion criteria, if deleted do not replace, do not duplicate"
    },
    "Exclusion Criterion": {
        "name": "Exclusion Criterion",
        "data_type": "Text",
        "definition": "C25370\nFor review purpose, see definition of the controlled terminology below\nList of characteristics in a protocol, any one of which excludes a potential subject from participation in a study. (CDISC glossary)",
        "guidance": "Add criteria as needed. the criteria sequentially",
        "conformance": "Required",
        "cardinality": "One to many",
        "relationship": "5.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: to Number #, 5.3 Exclusion Criteria\nConcept: C25370",
        "repeating": "Yes, repeatable for each exclusion criterion, if deleted do not replace, do not duplicate"
    },
    "Definitions Related to Childbearing Potential": {
        "name": "Definitions Related to Childbearing Potential",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of participants of childbearing potential and non-childbearing potential within the context of a trial, or state not applicable.",
        "guidance": "Specify the definitions of:\narticipant of childbearing potential\n\narticipant of nonchildbearing potential",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.4.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.4.1 Definitions Related to Childbearing Potential\nConcept: CNEW",
        "repeating": "No"
    },
    "Contraception Requirements": {
        "name": "Contraception Requirements",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the prevention of conception or impregnation by the use of devices or drugs or surgery within a context of a trial l, or state not applicable. ",
        "guidance": "Specify the: \nontraceptive methods required \nuration of use",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.4.2 Contraception requirements\nConcept: CNEW",
        "repeating": "No"
    },
    "Lifestyle Restrictions": {
        "name": "Lifestyle Restrictions",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to trial participant lifestyle such as diet, substance intake, and physical or other daily activities.",
        "guidance": "In the following subsections, describe any restrictions during the trial pertaining to lifestyle and/or diet, intake of caffeine, alcohol, or tobacco, or physical and other activities. If not applicable, include a statement that no restrictions are required. ",
        "conformance": "Conditional: If Level 3 subheadings are not used",
        "cardinality": "One to one",
        "relationship": "5.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.5\t Lifestyle Restrictions\nConcept: CNEW",
        "repeating": "No"
    },
    "Meals and Dietary Restrictions": {
        "name": "Meals and Dietary Restrictions",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the restrictions related to participant diet during the trial.",
        "guidance": "If applicable, describe any restrictions on diet (e.g., food and drink restrictions, timing of meals relative to dosing). ",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "5.5.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.5.1 Meals and Dietary Restrictions\nConcept: CNEW",
        "repeating": "No"
    },
    "Caffeine Alcohol Tobacco and Other Restrictions": {
        "name": "Caffeine Alcohol Tobacco and Other Restrictions",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the restrictions related to participant intake of caffeine, alcohol, tobacco, and other habit-forming substances during the trial.",
        "guidance": "If applicable, describe any restrictions on the intake of caffeine, alcohol, tobacco, or other restrictions. \n",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "5.5.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.2.2 Caffeine, Alcohol, Tobacco, and Other Restrictions\nConcept: CNEW",
        "repeating": "No"
    },
    "Physical Activity Restrictions": {
        "name": "Physical Activity Restrictions",
        "data_type": "Text",
        "definition": "C17708\nFor review purpose, see definition of the controlled terminology below\nAny form of exercise or movement. Physical activity may include planned activity such as walking, running, basketball, or other sports. Physical activity may also include other daily activities such as household chores, yard work, walking the dog, etc.",
        "guidance": "If applicable, describe any restrictions on activity (e.g., in first-in-human trials, activity may be restricted by ensuring participants remain in bed for 4 to 6 hours after dosing). ",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "5.5.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.5.3 Physical Activity Restrictions\nConcept: C17708",
        "repeating": "No"
    },
    "Other Activity Restrictions": {
        "name": "Other Activity Restrictions",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn activity that is different than the one(s) previously specified or mentioned.",
        "guidance": "If applicable, describe restrictions on any other activity (e.g., blood or tissue donation, driving, heavy machinery use, or sun exposure).",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "5.5.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.5.4 Other Activity Restrictions\nConcept: CNEW",
        "repeating": "No"
    },
    "Screen Failure": {
        "name": "Screen Failure",
        "data_type": "Text",
        "definition": "C49628\nFor review purpose, see definition of the controlled terminology below\nThe potential subject who does not meet eligibility (inclusion/exclusion) criteria during the screening period.",
        "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: C49628",
        "repeating": "No"
    },
    "Rescreening": {
        "name": "Rescreening",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe process of active consideration of subjects for enrolment in a trial, for those potential subjects who have failed a prior screening attempt.",
        "guidance": "Describe screen failure and indicate how screen failure will be handled in the trial, including conditions and criteria upon which rescreening is acceptable. If applicable, indicate the circumstances and time window under which a repeat procedure is allowed for screen failure relating to specific inclusion/exclusion criteria for the trial.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "5.6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 5.6 Screen Failure and Rescreening\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of the overview of trial interventions or a heading for the optional table below": {
        "name": "Description of the overview of trial interventions or a heading for the optional table below",
        "data_type": "Text",
        "definition": "",
        "guidance": "Trial interventions are all pre-specified, investigational and non-investigational medicinal products, medical devices or other interventions intended for the participants during the trial. The investigational trial intervention is the product used in the trial as part of trial objectives. Description of investigational trial intervention is provided in Section 6.1. Other trial interventions that are not part of trial objectives (not an investigational role in this trial) are described in Section 6.9 Description of Non-investigational trial interventions. \nAny regional requirements should be noted in the appropriate subsections. \nProvide an overview of investigational and non-investigational trial interventions. Classify the trial intervention as IMP, NIMP/AxMP designations based on study design and local legislation. Consider the optional table below",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "6",
        "value": "",
        "business_rules": "Value Allowed: Yes\nRelationship: 6 TRIAL INTERVENTION AND CONCOMITANT THERAPY\nConcept: ",
        "repeating": "No"
    },
    "Arm Name": {
        "name": "Arm Name",
        "data_type": "Text",
        "definition": "C93729\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the arm.",
        "guidance": "N/A",
        "conformance": "Optional: if the table used",
        "cardinality": "One to many; one to interventions for arm name",
        "relationship": "6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: arm name \nConcept: C93729",
        "repeating": "Yes, repeatable for each arm name and intervention and use combination"
    },
    "Intervention Name": {
        "name": "Intervention Name",
        "data_type": "Text",
        "definition": "C177930\nFor review purpose, see definition of the controlled terminology below\nThe literal identifier (i.e. distinctive designation) for the study intervention.",
        "guidance": "N/A",
        "conformance": "Optional: if the table used",
        "cardinality": "One to arm name and arm type",
        "relationship": "6",
        "value": "Nonproprietary name or ponsor ",
        "business_rules": "Value Allowed: Yes\nRelationship: Arm name and intervention name, \nConcept: C177930",
        "repeating": "Yes, repeatable for each arm name and arm type"
    },
    "Dosage Strengths": {
        "name": "Dosage Strengths",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe strength of a drug product, which indicates the amount of each active ingredient in a given dosage form, measured in units of volume or concentration.",
        "guidance": "N/A",
        "conformance": "Optional: if the table used",
        "cardinality": "One to each dosage formulation ",
        "relationship": "Trial Intervention and Concomitant Therapy",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose strength, 6 Trial Intervention and Concomitant Therapy\nConcept: CNEW",
        "repeating": "Yes, repeatable for each intervention and formulation per arm name and arm type"
    },
    "Dosage Levels": {
        "name": "Dosage Levels",
        "data_type": "Text",
        "definition": "C94394\nFor review purpose, see definition of the controlled terminology below\nSpecified quantity of a medicine, to be taken at one time or at stated intervals. [ISO 11615:2012 Health Informatics]",
        "guidance": "N/A",
        "conformance": "Optional: if the table used",
        "cardinality": "One to each intervention and dosage formulation",
        "relationship": "6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: arm name and dose level\n\nConcept: C94394",
        "repeating": "Yes, repeatable for each intervention, dose formulation, dosage strength and dosage level per arm "
    },
    "RegimenTreatment PeriodVaccination regimen": {
        "name": "RegimenTreatment PeriodVaccination regimen",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the schedule and periodicity of a treatment or vaccination regimen.",
        "guidance": "N/A",
        "conformance": "Optional: if the table used",
        "cardinality": "One to each intervention, dose formulation, dosage strength per arm",
        "relationship": "6",
        "value": "Regimen/Treatment Period",
        "business_rules": "Value Allowed: Yes\nRelationship: arm name and regimen/treatment period/vaccine regimen, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each arm name"
    },
    "Description of Investigational Trial Intervention": {
        "name": "Description of Investigational Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the investigational trial intervention.",
        "guidance": "Describe the investigational trial intervention to be administered in each arm of the trial and for each period of the trial including route and mode of administration, dose, dosage regimen, duration of intervention, use, packaging and labelling. \nRefer to approved regional labelling, as appropriate. \nFor drug/device combination products, include details on the configuration and use of the device and device manufacturer. A device user manual may be referenced in this section.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "6.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.1 Description of Investigational Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Additional Text if Needed": {
        "name": "Additional Text if Needed",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nExtra or further descriptive text that is optionally added as needed.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "6.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.1 Description of Investigational Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Rationale for Investigational Trial Intervention Dose and Regimen": {
        "name": "Rationale for Investigational Trial Intervention Dose and Regimen",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
        "guidance": "Provide a rationale for the selection of the dose(s) or dose range, pharmaceutical dose form, the route of administration, and dosing regimen of the investigational trial intervention, as applicable. This rationale should include relevant results from previous nonclinical studies and clinical trials that support selection of the dose and regimen. Discuss impact of differences in study population characteristics (for example, age, sex and/or race) which could lead to differences in pharmacokinetics and pharmacodynamics in this study as compared to previous studies. If applicable, justify any differences in dose regimen or therapeutic use relative to approved labelling. Describe prior trials and other information that support the dose and/or dose regimen of the investigational intervention.\nInclude a rationale for prospective dose adjustments incorporated in the trial, if any.\u00a0",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "6.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.2 Rationale for Investigational Trial Intervention Dose and Regimen\nConcept: CNEW",
        "repeating": "No"
    },
    "Investigational Trial Intervention Administration": {
        "name": "Investigational Trial Intervention Administration",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nAn explanation as to the scientific reasons for the choice of the trial intervention dose and dose regimen.",
        "guidance": "Describe the detailed procedures for administration of each participant\u2019s dose of each investigational trial intervention. This may include the timing of dosing (for example, time of day, interval), the duration (for example, the length of time participants will be administered the investigational trial intervention), and the timing of dosing relative to meals. \nInclude any specific instructions to trial participants about when or how to prepare and take the dose(s) and how delayed or missed doses should be handled. \nDose escalation or cohort expansion as part of the overall design should be covered in Section 4.1 Description of Trial Design.\u00a0\n",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "6.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.3 Investigational Trial Intervention Administration\nConcept: CNEW",
        "repeating": "No"
    },
    "Investigational Trial Intervention Dose Modification": {
        "name": "Investigational Trial Intervention Dose Modification",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA change, alteration, or adjustment to the dose of a investigational trial intervention.",
        "guidance": "For each participant, describe any dose modifications allowed, including conditions for such dose modifications, particularly regarding failure to respond or safety concerns. State any minimum period required before a participant\u2019s dose might be raised to the next higher dose or dose range. Include whether it is permissible to start and stop treatment and how dose reductions (if permitted) are to be managed. \nInformation on stopping investigational trial intervention for participants due to safety/other reasons should be detailed in Section 7 Participant Discontinuation of Trial Intervention and Discontinuation or Withdrawal from Trial.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "6.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.4 Investigational Trial Intervention Dose Modification\nConcept: CNEW",
        "repeating": "No"
    },
    "Management of Investigational Trial Intervention Overdose": {
        "name": "Management of Investigational Trial Intervention Overdose",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how a potential investigational trial intervention overdose will be handled.",
        "guidance": "Describe what is meant by investigational trial intervention overdose. Provide any available information on managing the overdose and ensure it is consistent with the Investigator\u2019s Brochure or product labelling. Cross-references these documents as applicable. ",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.5 Management of Investigational Trial Intervention Overdose\nConcept: CNEW",
        "repeating": "No"
    },
    "Preparation of Investigational Trial Intervention": {
        "name": "Preparation of Investigational Trial Intervention",
        "data_type": "Text",
        "definition": "C176274\nFor review purpose, see definition of the controlled terminology below\nThe way in which the investigational trial intervention is prepared for use or administration to the study participant.",
        "guidance": "Describe any preparation of the investigational trial intervention, and when necessary, by whom. When applicable, describe the maximum hold time once thawed/mixed before administration. Include thawing, diluting, mixing, and reconstitution/preparation instructions. For drug/device combination products, include any relevant assembly or use instructions and reference the package insert that is provided separately.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents.\u00a0\n",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.6.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.6.1 Preparation of Investigational Trial Intervention\nConcept: C176274",
        "repeating": "No"
    },
    "Storage and Handling of Investigational Trial Intervention": {
        "name": "Storage and Handling of Investigational Trial Intervention",
        "data_type": "Text",
        "definition": "C115525\nFor review purpose, see definition of the controlled terminology below\nThe safe handling, storage, distribution, and return of unused investigational trial intervention.",
        "guidance": "Describe storage and handling requirements (for example, protection from light, temperature, humidity) for the investigational trial intervention(s). For trials in which multi-dose vials are utilised, provide additional information regarding stability and expiration time after initial use (for example, the seal is broken).\u00a0\nState how the investigational trial intervention(s) will be provided to the Investigator. If applicable, describe the kits, packaging, or other material of the investigational trial intervention for blinding purposes.\u00a0\nIf the instructions are lengthy or complicated, it is acceptable to reference the package insert (if applicable) or include instructions in a separate document(s) provided to the site (for example, a pharmacy manual). If the latter, reference the separate documents. ",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.6.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.6.2 Storage and Handling of Investigational Trial Intervention\nConcept: C115525",
        "repeating": "No"
    },
    "Accountability of Investigational Trial Intervention": {
        "name": "Accountability of Investigational Trial Intervention",
        "data_type": "Text",
        "definition": "C176267\nFor review purpose, see definition of the controlled terminology below\nThe act or process for documenting the storage, inventory tracking, and disposition of the investigational trial intervention.",
        "guidance": "Describe the method by which the accountability will be achieved, including trial intervention will be distributed and related details, including:\nhow and by whom the trial intervention will be distributed\nparticipation of a drug repository or pharmacy, if applicable, \nplans for disposal or return of unused product\nif applicable, plans for reconciliation of investigational trial intervention",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.6.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.6.3 Accountability of Trial Intervention\nConcept: C176267",
        "repeating": "No"
    },
    "Participant Assignment to Investigational Trial Intervention": {
        "name": "Participant Assignment to Investigational Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe technique used to assign trial participants to a trial arm.",
        "guidance": "Describe the method of assigning participants to investigational trial intervention without being so specific that blinding or randomisation might be compromised. If assignment to investigational trial intervention is by randomisation, describe when randomisation occurs relative to screening. State that at enrollment, participant identification codes should be assigned. \nIf adaptive randomisation or other methods of covariate balancing/minimisation are employed, include a cross-reference to the methods of analysis in Section 10 Statistical Considerations. As applicable, details regarding the implementation of procedures to minimise bias should be described.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.7.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.7.1 Participant Assignment to Investigational Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Randomisation": {
        "name": "Randomisation",
        "data_type": "Text",
        "definition": "C25196\nFor review purpose, see definition of the controlled terminology below\nThe process of assigning trial subjects to treatment or control groups using an element of chance to determine the assignments in order to reduce bias. [ICH E6 1.48]",
        "guidance": "Describe the randomisation procedures (for example, central randomisation procedures), the method used to generate the randomisation schedule (for example, computer generated), the source of the randomisation schedule (for example, sponsor, investigator, or other), and whether IxRS will be used. To maintain the integrity of the blinding, do not include the block size. ",
        "conformance": "Conditional: when randomised trial",
        "cardinality": "One to one",
        "relationship": "6.7.2 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.7.2 Randomisation\nConcept: C25196",
        "repeating": "No"
    },
    "Blinding": {
        "name": "Blinding",
        "data_type": "Text",
        "definition": "C189349\nFor review purpose, see definition of the controlled terminology below\nThe methodology used for enacting trial blinding.",
        "guidance": "Describe efforts to ensure that the investigational trial intervention(s) are as indistinguishable as possible. Plans for the maintenance of randomisation codes and appropriate blinding for the trial should be described. Procedures for planned (e.g. Interim Analysis), and unintentional (e.g. breach of procedure) breaking of randomisation codes should be provided. For unplanned but intentional actions (e.g. safety events), refer to Section 6.7.4 Emergency Unblinding at the Site.\nIf the trial allows for some investigators or other designated staff to remain unblinded (for example, to allow them to adjust investigational trial intervention), the means of maintaining the blinding for other investigators or staff should be explained. Measures to prevent unblinding by laboratory measurements or while performing study assessments, if used, should be described. ",
        "conformance": "Conditional: when blind trial ",
        "cardinality": "One to one",
        "relationship": "6.7.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.7.3 Blinding\nConcept: C189349",
        "repeating": "No"
    },
    "Emergency Unblinding at the Site": {
        "name": "Emergency Unblinding at the Site",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the methodology used for unblinding of the trial treatment in the case of a sudden unforeseen crisis that requires immediate medical care of the participant. ",
        "guidance": "Describe the criteria for breaking the trial blind or participant code. Describe the circumstances in which the blinding would be broken for an individual or for all participants and who has responsibility. Include the procedure for emergency unblinding such as via IxRS or code envelopes as well as documentation of unblinding. Indicate to whom the intentional and unplanned unblinding should be reported.",
        "conformance": "Conditional: when blind trial ",
        "cardinality": "One to one",
        "relationship": "6.7.4 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.7.4 Emergency Unblinding at the Site\nConcept: CNEW",
        "repeating": "No"
    },
    "Investigational Trial Intervention  ": {
        "name": "Investigational Trial Intervention  ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the measures taken to ensure trial intervention compliance, including mandatory documentation to be filled out and the source data that will be used to document investigational trial intervention compliance.",
        "guidance": "Describe the measures to monitor and document participants\u2019 compliance with investigational intervention (e.g. study intervention accountability records, diary cards, or investigational intervention concentration measurements).\nList what documents are mandatory to complete (for example, participant drug log) and what source data/records will be used to document investigational intervention compliance. ",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.8",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.8 Investigational Trial Intervention \nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Nonnvestigational Trial Intervention": {
        "name": "Description of Nonnvestigational Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative representation of the non-investigational trial intervention",
        "guidance": "As stated in Section 6, non-investigational interventions are products used in the trial but are not part of trial objectives and hence, are not investigational trial interventions. \nThe non-investigational trial intervention(s) may be described concisely in a table or in the following sections as applicable.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.9",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.9 Description of Nonnvestigational Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Background Trial Intervention": {
        "name": "Background Trial Intervention",
        "data_type": "Text",
        "definition": "C165822\nFor review purpose, see definition of the controlled terminology below\nMedicinal products that are administered to each clinical trial subject, regardless of randomization group, a) to treat the indication which is the object of the study, or b) required in the protocol as part of standard care for a condition that is not the indication under investigation, and is relevant for the clinical trial design. [After Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
        "guidance": "Describe permitted background intervention(s), including administration and any conditions for use.",
        "conformance": "Conditional: when any background interventions are defined ",
        "cardinality": "One to one",
        "relationship": "6.9.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.9.1 Background Trial Intervention\nConcept: C165822",
        "repeating": "No"
    },
    "Rescue Therapy": {
        "name": "Rescue Therapy",
        "data_type": "Text",
        "definition": "C165835\nFor review purpose, see definition of the controlled terminology below\nMedicinal products identified in the protocol as those that may be administered to subjects when the efficacy of the investigational medicinal product (IMP) is not satisfactory, the effect of the IMP is too great and is likely to cause a hazard to the patient, or to manage an emergency situation. [After EU-CTR Recommendations from the expert group on clinical trials for the implementation of Regulation (EU) No 536/2014' dd 28 June 2017]",
        "guidance": "List all permitted rescue medications, treatments, and/or procedures, including any relevant instructions about administration and any conditions for use. \nIf administration of rescue therapy leads to the temporary discontinuation of trial intervention or a participant\u2019s withdrawal from the trial, refer to Section 7 Participant Discontinuation of Trial Intervention and Withdrawal from Trial. ",
        "conformance": "Conditional: when any rescue therapies are defined ",
        "cardinality": "One to one",
        "relationship": "6.9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.9.2 Rescue Therapy\nConcept: C165835",
        "repeating": "No"
    },
    "Other Noninvestigational ": {
        "name": "Other Noninvestigational ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA non-investigational trial therapy that is different than the one(s) previously specified or mentioned.",
        "guidance": "If applicable, describe the use of any other non-investigational intervention, for example, challenge agents or diagnostics.",
        "conformance": "Conditional: when any other non-investigational interventions are defined",
        "cardinality": "One to one",
        "relationship": "6.9.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.9.3 Other Noninvestigational Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Concomitant Therapy": {
        "name": "Concomitant Therapy",
        "data_type": "Text",
        "definition": "C53630\nFor review purpose, see definition of the controlled terminology below\nAny pharmaceutical agent, other than the trial interventions, that is administered to or used by the subject prior to or during a specified time period.",
        "guidance": "Describe the concomitant medications, supplements, complementary and alternative therapies, treatments, and/or procedures which are prohibited or permitted during the trial and include details about when the information will be collected (for example, screening, all visits). \nThis section should be consistent with the medication restrictions in the inclusion/exclusion criteria. \nWhen appropriate to separate the content, subheadings may be used.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "6.10",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.10 Concomitant Therapy\nConcept: C53630",
        "repeating": "No"
    },
    "Prohibited Concomitant Therapy": {
        "name": "Prohibited Concomitant Therapy",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is banned from use in the trial.",
        "guidance": "If applicable, describe any prohibited concomitant therapy.",
        "conformance": "Conditional: when any prohibited concomitant therapies are defined",
        "cardinality": "One to one",
        "relationship": "6.10.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.10.1 Prohibited Concomitant Therapy\nConcept: CNEW",
        "repeating": "No"
    },
    "Permitted Concomitant Therapy ": {
        "name": "Permitted Concomitant Therapy ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nConcomitant therapy that is approved for use in the trial.",
        "guidance": "If applicable, describe any permitted concomitant therapy.",
        "conformance": "Conditional: when any permitted concomitant therapies are defined ",
        "cardinality": "One to one",
        "relationship": "6.10.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 6.10.2 Permitted Concomitant Therapy\nConcept: CNEW",
        "repeating": "No"
    },
    "Permanent Discontinuation of Trial Intervention": {
        "name": "Permanent Discontinuation of Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to permanently discontinue the administration of trial intervention.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "7.1.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 7.1.1 Permanent Discontinuation of Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Temporary Discontinuation of Trial Intervention": {
        "name": "Temporary Discontinuation of Trial Intervention",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to temporarily discontinue the administration of trial intervention.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "7.1.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 7.1.2 Temporary Discontinuation of Trial Intervention\nConcept: CNEW",
        "repeating": "No"
    },
    "Rechallenge": {
        "name": "Rechallenge",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to reintroduce previously withdrawn or temporarily discontinued medical intervention in the same patient.",
        "guidance": "Describe the criteria for rechallenge/restarting trial intervention, how to perform rechallenge, number of rechallenges allowed during the trial, and whether all, or specify which, assessments will be performed for the stated duration of the trial.\nIf rechallenge is not allowed, state this.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "7.1.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 7.1.3 Rechallenge\nConcept: CNEW",
        "repeating": "No"
    },
    "Participant Discontinuation or Withdrawal from Trial": {
        "name": "Participant Discontinuation or Withdrawal from Trial",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe rationale for why the participant either discontinued or withdrawal from the trial.",
        "guidance": "Describe the criteria for participant discontinuation or withdrawal from the trial.\nDescribe the reason for withdrawal and the type of data to be collected for the final assessments with reference to the schedule of activities for the participant\u2019s end of study visit unless provided in another section. \nIn many cases, the only reason for a participant being considered withdrawn from the trial should be a participant\u2019s withdrawal of consent to continue to participate in the trial. All other participants, including those who discontinue treatment, should remain in the trial and continue to be followed to prevent missing data in important analyses. Refer to Section 10 Statistical Considerations for the data that must be collected for the trial estimands.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "7.2",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 7.2 Participants Discontinuation or Withdrawal from the Trial\nConcept: CNEW",
        "repeating": "No"
    },
    "Los to FollowUp": {
        "name": "Los to FollowUp",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe mitigation strategies to be employed for the loss or lack of continuation of a participant to follow-up, including the frequency by which follow-up occurs.",
        "guidance": "Describe how the trial will define how participants are lost to follow-up. In general, participants should be considered lost to follow-up only if they cannot be reached despite multiple attempts contact. Also describe approaches that will be used to minimise loss to follow-up, such as multiple, diverse methods to remain in contact with participants (e.g., telephone calls, texts, and emails to the participant) and how contacts will be recorded.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "7.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 7.3 Los to Follow-up\nConcept: CNEW",
        "repeating": "No"
    },
    "Trial Assessments and Procedures Considerations": {
        "name": "Trial Assessments and Procedures Considerations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of general considerations applicable across trial assessments and procedures.",
        "guidance": "Describe general considerations applicable across trial assessments and procedures.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "8.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.1 Trial Assessments and Procedures Considerations\nConcept: CNEW",
        "repeating": "No"
    },
    "Screening Assessments and Procedures": {
        "name": "Screening Assessments and Procedures",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the screening epoch of the trial.",
        "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
        "repeating": "No"
    },
    "Baseline Assessments and Procedures": {
        "name": "Baseline Assessments and Procedures",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to the baseline epoch of the trial.",
        "guidance": "Describe any assessments and procedures that are unique to screening/baseline (e.g., collection of data on participant characteristics, assessments/procedures performed for the purpose of determining eligibility or for stratification) in this section. Describe screening and baseline assessments and procedures separately when screening and baseline are different or performed at different visits.",
        "conformance": "Conditional: when the Baseline Assessments and Procedures are different from Screening",
        "cardinality": "One to one",
        "relationship": "8.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.2 Screening/Baseline Assessments and Procedures\nConcept: CNEW",
        "repeating": "No"
    },
    "Efficacy Assessments and Procedures": {
        "name": "Efficacy Assessments and Procedures",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial assessments and procedures related to trial intervention efficacy.",
        "guidance": "Describe efficacy assessments and procedures in this section. Cross Section 8.7 Immunogenicity Assessments if immunogenicity assessments are used in efficacy determination.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "8.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.3 Efficacy Assessments and Procedures\nConcept: CNEW",
        "repeating": "No"
    },
    "Safety Assessments and Procedures": {
        "name": "Safety Assessments and Procedures",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the assessments and procedures related to participant safety within the trial.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "8.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4 Safety Assessments and Procedures\nConcept: CNEW",
        "repeating": "No"
    },
    "Physical Examination": {
        "name": "Physical Examination",
        "data_type": "Text",
        "definition": "C20989\nFor review purpose, see definition of the controlled terminology below\nThe procedures for a systemic evaluation of the body and its functions using visual inspection, palpation, percussion and auscultation.",
        "guidance": "Include any specific instructions for the collection and interpretation of physical examinations.",
        "conformance": "Conditional: when Physical Exams are required ",
        "cardinality": "One to one",
        "relationship": "8.4.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.1 Physical Examination\nConcept: C20989",
        "repeating": "No"
    },
    "Vital Signs": {
        "name": "Vital Signs",
        "data_type": "Text",
        "definition": "C154628\nFor review purpose, see definition of the controlled terminology below \nThe procedures for measurements of the body's basic functions that provide insight into the health status of the person.",
        "guidance": "Include any specific instructions for the collection and interpretation of vital signs. ",
        "conformance": "Conditional: when Vital Signs are required",
        "cardinality": "One to one",
        "relationship": "8.4.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.2 Vital Signs\nConcept: C154628",
        "repeating": "No"
    },
    "Electrocardiograms": {
        "name": "Electrocardiograms",
        "data_type": "Text",
        "definition": "C168186\nFor review purpose, see definition of the controlled terminology below\nThe procedures for the recordings produced by the variations in electrical potential caused by electrical activity of the heart muscle and detected at the body surface, as a method for studying the action of the heart muscle.",
        "guidance": "Include any specific instructions for the collection, interpretation, and archiving of ECGs.",
        "conformance": "Conditional: when Electrocardiograms are required",
        "cardinality": "One to one",
        "relationship": "8.4.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.3 Electrocardiograms\nConcept: C168186",
        "repeating": "No"
    },
    "Clinical Safety Laboratory Assessments": {
        "name": "Clinical Safety Laboratory Assessments",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nTrial-related laboratory assessments and procedures related to participant safety.",
        "guidance": "",
        "conformance": "Conditional: when Clinical Laboratory Assessments are required",
        "cardinality": "One to one",
        "relationship": "8.4.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.4 Clinical Laboratory Assessments\nConcept: CNEW",
        "repeating": "No"
    },
    "Pregnancy Testing": {
        "name": "Pregnancy Testing",
        "data_type": "Text",
        "definition": "C92949\nFor review purpose, see definition of the controlled terminology below\nAny examination performed to assess if a female is gravid.",
        "guidance": "Include any specific instructions for the collection and interpretation of pregnancy testing. ",
        "conformance": "Conditional: when Pregnancy Testing is required",
        "cardinality": "One to one",
        "relationship": "8.4.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.5 Pregnancy Testing\nConcept: C92949",
        "repeating": "No"
    },
    "Suicidal Ideation and Behaviour Risk Monitoring": {
        "name": "Suicidal Ideation and Behaviour Risk Monitoring",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of data collection procedures and analysis related to suicidal ideation and behaviour risk monitoring.",
        "guidance": "If the trial meets any of the criteria requiring suicidal ideation and behaviour risk monitoring by the guidance/guideline in each region, include justification for the need for suicidal ideation and behaviour risk monitoring in the study and add any specific instructions for the collection and interpretation of the assessment. In case this is an AESI in the study, justification should also be provided in Section 9.2.4 Adverse Events of Special Interest.",
        "conformance": "Conditional: when Suicidal Ideation and Behaviour Risk Monitoring are required",
        "cardinality": "One to one",
        "relationship": "8.4.6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.4.6 Suicidal Ideation and Behaviour Risk Monitoring\nConcept: CNEW",
        "repeating": "No"
    },
    "Pharmacokinetics": {
        "name": "Pharmacokinetics",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacokinetic assessments within the trial.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.5 Pharmacokinetics\nConcept: CNEW",
        "repeating": "No"
    },
    "Genetics and Pharmacogenomics": {
        "name": "Genetics and Pharmacogenomics",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in genetic and pharmacogenomic biomarker assessments within the trial.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.6.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.6.1 Genetics and Pharmacogenomics\nConcept: CNEW",
        "repeating": "No"
    },
    "Pharmacodynamic Biomarkers": {
        "name": "Pharmacodynamic Biomarkers",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in pharmacodynamic biomarker assessments within the trial.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.6.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.6.2 Pharmacodynamic Biomarkers\nConcept: CNEW",
        "repeating": "No"
    },
    "Other Biomarkers": {
        "name": "Other Biomarkers",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in other biomarker assessments within the trial.",
        "guidance": "",
        "conformance": "Conditional: when Other Biomarkers are required",
        "cardinality": "One to one",
        "relationship": "8.6.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.6.3 Other Biomarkers\nConcept: CNEW",
        "repeating": "No"
    },
    "Immunogenicity Assessments": {
        "name": "Immunogenicity Assessments",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about the collection, use, and retention of biospecimens, and their use in immunogenicity assessments within the trial.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.7",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.7 Immunogenicity Assessments\nConcept: CNEW",
        "repeating": "No"
    },
    "Medical Resource Utilisation and Health Economics": {
        "name": "Medical Resource Utilisation and Health Economics",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA narrative description containing information about medical resource utilization and the health outcome measures, collection method and participant burden.",
        "guidance": "This section does not apply to COAs. Include this section only for any value evidence and outcomes assessments not included in either the efficacy or safety sections.\nDescribe the health outcome measures, collection method (e.g., diary, physician interview), and participant burden.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "8.8",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 8.8 Medical Resource Utilisation and Health Economics\nConcept: CNEW",
        "repeating": "No"
    },
    "Definitions of Adverse Events": {
        "name": "Definitions of Adverse Events",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of adverse events within the context of the trial. ",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.1.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.1.1 Definitions of Adverse Events\nConcept: CNEW",
        "repeating": "No"
    },
    "Definitions of Serious Adverse Events": {
        "name": "Definitions of Serious Adverse Events",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of serious adverse events within the context of the trial.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.1.2",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.1.2 Definitions of Serious Adverse Events\nConcept: CNEW",
        "repeating": "No"
    },
    "Definition of Medical Device Product Complaints": {
        "name": "Definition of Medical Device Product Complaints",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise explanation of the meaning of medical device product complaints within the context of the trial.",
        "guidance": "N/A",
        "conformance": "Conditional: when there is Medical Device Product Complaints",
        "cardinality": "One to one",
        "relationship": "9.1.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.1.3 Definition of Medical Device Product Complaints\nConcept: CNEW",
        "repeating": "No"
    },
    "Situational Scope": {
        "name": "Situational Scope",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the specific circumstances and context in which safety events are collected and monitored.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type"
    },
    "Reportable Period Start": {
        "name": "Reportable Period Start",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will begin for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type "
    },
    "Reportable Period End": {
        "name": "Reportable Period End",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date on which reporting will cease for trial related events such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events.",
        "guidance": "N/A",
        "conformance": "Optional ",
        "cardinality": "One to one",
        "relationship": "9.2 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type"
    },
    "Timing for Reporting to Sponsor or Designee": {
        "name": "Timing for Reporting to Sponsor or Designee",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type "
    },
    "Method for Reporting": {
        "name": "Method for Reporting",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the technique by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
        "guidance": "N/A",
        "conformance": "Optional ",
        "cardinality": "One to one",
        "relationship": "9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type"
    },
    "Backup Method for Reporting": {
        "name": "Backup Method for Reporting",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of alternative techniques by which trial related events, such as adverse events, serious adverse events, product complaints, medical device product complaints, and pregnancy and postpartum events, are reported to the sponsor and/or regulatory authority.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "9.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Event Type, \nConcept: CNEW",
        "repeating": "Yes, repeatable for each event type"
    },
    "Timing": {
        "name": "Timing",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the timing window between trial related events and their reporting to the sponsor or designee.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "9.2.1",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.2.1 Timing\nConcept: CNEW",
        "repeating": "No"
    },
    "Identification": {
        "name": "Identification",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA summary of the identification, recording, assessments of severity and causality, and follow-up of adverse events, serious adverse events, pregnancy and postpartum events, and medical device product complaints.",
        "guidance": "Specify .",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "9.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.2.2 Collection Procedures\nConcept: CNEW",
        "repeating": "No"
    },
    "Severity": {
        "name": "Severity",
        "data_type": "Text",
        "definition": "C25676\nFor review purpose, see definition of the controlled terminology below \nThe evaluation of the intensity (severity) of an event.",
        "guidance": "Specify the intensity rating categories/scale.",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Severity\nConcept: C25676",
        "repeating": "No"
    },
    "Causality": {
        "name": "Causality",
        "data_type": "Text",
        "definition": "C82552\nFor review purpose, see definition of the controlled terminology below\nThe evaluation of the degree of causality (attributability) between a trial intervention and an event.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Causality\nConcept: C82552",
        "repeating": "No "
    },
    "Recording": {
        "name": "Recording",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description for the procedures used to document an event.",
        "guidance": "Specify procedures for recording.",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Recording\nConcept: CNEW",
        "repeating": "No "
    },
    "Followup": {
        "name": "Followup",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the procedures for follow-up, including the assessment tools that will be used to monitor an event and the duration of follow-up.",
        "guidance": "Specify the procedures for follow-up. Include the assessment tools that will be used to monitor the events and the duration of follow-up after appearance of the events.",
        "conformance": "Required ",
        "cardinality": "One to one ",
        "relationship": "9.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: Follow-up\nConcept: CNEW",
        "repeating": "No "
    },
    "Reporting": {
        "name": "Reporting",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the method and timelines for reporting an event to the sponsor.",
        "guidance": "Specify the reporting method (e.g., an electronic data collection tool or a paper CRF) and reporting timeline to the Sponsor.",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "9.2.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3 Reporting\nConcept: CNEW",
        "repeating": "No"
    },
    "Regulatory Reporting Requirements": {
        "name": "Regulatory Reporting Requirements",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the requirements for the sponsor/designee to report a serious adverse event, including the criteria for reporting, to the relevant regulatory authority.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "9.2.3.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.2.3.1 Regulatory Reporting Requirements\nConcept: CNEW",
        "repeating": "No"
    },
    "Adverse Events of Special Interest or state Not applicable": {
        "name": "Adverse Events of Special Interest or state Not applicable",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to define, measure, confirm, and report the occurrence of adverse events that are of special interest to the specific trial, or state not applicable.",
        "guidance": "",
        "conformance": "Required ",
        "cardinality": "One to one",
        "relationship": "9.2.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.2.4 Adverse Events of Special Interest\nConcept: CNEW",
        "repeating": "No"
    },
    "Participants Who Become Pregnant During the Trial": {
        "name": "Participants Who Become Pregnant During the Trial",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant who becomes pregnant while the participant is in the trial, as well as data collection about the child.",
        "guidance": "",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "9.3.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.3.1 Participants Who Become Pregnant During the Trial\nConcept: CNEW",
        "repeating": "No"
    },
    "Participants Whose Partners Become Pregnant": {
        "name": "Participants Whose Partners Become Pregnant",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the processes and procedures used to collect pregnancy data for a trial participant's partner, who becomes pregnant while the participant is in the trial.",
        "guidance": "",
        "conformance": "Conditional: ",
        "cardinality": "One to one",
        "relationship": "9.3.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.3.2 Participants Whose Partners Become Pregnant\nConcept: CNEW",
        "repeating": "No"
    },
    "Special Safety Situations": {
        "name": "Special Safety Situations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA characterization or classification of those trial specific situations that are associated with the trial intervention(s) and require regulatory reporting, but that do not qualify as an adverse event or serious adverse event for the given trial.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "9.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 9.4 Special Safety Situations\nConcept: CNEW",
        "repeating": "No"
    },
    "General Considerations": {
        "name": "General Considerations",
        "data_type": "Text",
        "definition": "C164387\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the planned conduct of statistical analyses within the context of the trial.",
        "guidance": "Provide statements relevant to statistical considerations in general. For example, this might include statements indicating whether there is a separate statistical analysis plan, which general summary statistics will be provided, and when the analyses will be conducted (e.g. \u201cThe analysis will be conducted on all participant data at the time the trial ends.\u201d).",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.1 General Considerations, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: C164387",
        "repeating": "No"
    },
    "Analysis Sets": {
        "name": "Analysis Sets",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the set of participants whose data are to be included in the analyses. ",
        "guidance": "Describe analysis sets to be considered at the trial level, i.e. the set of participants whose data are to be included in the analyses. For each analysis described in Section 10, it should be clear which analysis set should be used.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.2 Analysis Sets, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
        "repeating": "No"
    },
    "Analyses of Demographics and Other Baseline Variables": {
        "name": "Analyses of Demographics and Other Baseline Variables",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of analyses relevant to variables at baseline, for example demographics, related to the trial.",
        "guidance": "Describe the summary statistics that will be used to describe the distribution of demographic and other relevant variables at baseline. Specify the timing of the measurement of the variables (e.g., at inclusion in the trial; before, or at randomisation). Relevant variables include but are not limited to: stratification variables specified in Section 6.7 Investigational Trial Intervention Assignment, Randomisation and Blinding, covariates for the statistical models specified in Section 10.4 Analyses Associated with the Primary Objective(s), other suspected predictive or prognostic variables, and variables used for planned subgroup analyses.\n",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.3 Analyses of Demographics and Other Baseline Variables, 10 STATISTICAL CONSIDERATIONS and Table of Contents\nConcept: CNEW",
        "repeating": "No"
    },
    "Statistical Method of Analysis": {
        "name": "Statistical Method of Analysis",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each objective within the trial.",
        "guidance": "Describe the statistical analysis methods that will be used to evaluate the Secondary objective(s) and associated estimand(s) in Section 3.. Ensure that the statistical hypothesis/model/analysis (and corresponding assumptions) is aligned with the Secondary estimand(s). If there is more than one Secondary objective, present each objective as a level 3 heading and present each subsequent heading in Section 10.5 as a level 4 heading.\nFor each objective, state the null and alternative hypotheses, including the pre-planned type 1 error rate, or alternative criteria for evaluating whether the objective has been met, and relevant operating characteristics if appropriate. Describe the statistical model used and the factors that will be included (covariates and interactions) and any rules for handling these factors (for example, pooling of centres).\nIf modelling and simulation methods are to be used, please describe the model (inputs and outputs), the underlying assumptions, and the method of model fitting.",
        "conformance": "Conditional: when there is Secondary estimand",
        "cardinality": "One to one",
        "relationship": "10.5.X.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.5.1 Statistical Method\nConcept: CNEW",
        "repeating": ""
    },
    "Handling of Data in Relation to Primary Estimands": {
        "name": "Handling of Data in Relation to Primary Estimands",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the primary estimand.",
        "guidance": "For each intercurrent event of the primary estimand(s) (Section 3.1, Estimand(s) for the Primary Objective(s)), explain how data will be handled for the statistical analysis in line with the primary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "\n",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
        "repeating": ""
    },
    "Handling of Missing Data in Relation to Primary Estimand": {
        "name": "Handling of Missing Data in Relation to Primary Estimand",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the primary estimand will be handled, including the rationale for the approach.",
        "guidance": "Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "\n10.4.X.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
        "repeating": ""
    },
    "Sensitivity Analysis": {
        "name": "Sensitivity Analysis",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the series of analyses conducted to explore the robustness of inferences from the main estimator to deviations from its underlying modelling assumptions and limitations in the data.",
        "guidance": "Describe any supplementary analysis, if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
        "conformance": "Conditional: when there is Seconday Objective and sensitivity Analysis for a Secondary objective",
        "cardinality": "One to one",
        "relationship": "\n10.5.X.4",
        "value": "Text",
        "business_rules": "Value Allowed Yes\nRelationship: 10.5.4 Sensitivity Analysis\nConcept: CNEW",
        "repeating": ""
    },
    "Supplementary Analysis": {
        "name": "Supplementary Analysis",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
        "guidance": "Describe any supplementary analysis if applicable. Supplementary analyses are conducted in addition to the main and sensitivity analysis with the intent to provide additional insights into the understanding of the treatment effect.",
        "conformance": "Conditional: when there Supplementary Analysis for a Secondary objective",
        "cardinality": "One to one",
        "relationship": "\n10.5.X.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
        "repeating": ""
    },
    "Handling of Data in Relation to Secondary Estimands": {
        "name": "Handling of Data in Relation to Secondary Estimands",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how data will be handled for the statistical analysis in line with the Secondary estimand.",
        "guidance": "For each intercurrent event of the Secondary estimand(s) (Section 3.1, Estimand(s) for the Secondary Objective(s)), explain how data will be handled for the statistical analysis in line with the Secondary estimand. The handling of intercurrent events in statistical analysis should be aligned with the specific estimand strategies being used.\nThis section should describe with more detail the rationale and handling of the data rather than repeating the guidance from the preceding sections.",
        "conformance": "Conditional: when there is Secondary estimand",
        "cardinality": "One to one",
        "relationship": "\n10.5.X.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:10.5.2 Handling of Data in relation to Secondary Estimand(s)\nConcept: CNEW",
        "repeating": ""
    },
    "Handling of Missing Data in Relation to Secondary Estimand": {
        "name": "Handling of Missing Data in Relation to Secondary Estimand",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of how missing data associated with the Secondary estimand will be handled, including the rationale for the approach.",
        "guidance": " Describe how missing data will be addressed (e.g., imputation method and model), state the underlying assumptions, and provide a rationale for the approach.",
        "conformance": "Conditional: when there is Secondary estimand",
        "cardinality": "One to one",
        "relationship": "\n10.5.X.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.5.3 Handling of Missing Data in Relation to Secondary Estimand\nConcept: CNEW",
        "repeating": ""
    },
    "Analysis Associated with Exploratory Objectivess": {
        "name": "Analysis Associated with Exploratory Objectivess",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical model, hypothesis, and methods of analyses for each exploratory objective within the trial.",
        "guidance": "Describe any exploratory analyses, if applicable. Additional subsections could be created to describe the analyses, as needed. If there is no exploratory objective, indicate \u201cnot applicable\u201d",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.6",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.6 Analysis Associated with the Exploratory Objective(s),\nConcept: CNEW",
        "repeating": "No"
    },
    "Safety Analyses": {
        "name": "Safety Analyses",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses of relevant safety variables, including adverse events of special interest.",
        "guidance": "If safety is a primary and/or secondary objective, describe the corresponding safety analyses in the appropriate section above (Section 10.4 Analyses Associated with the Primary Objective(s) or Section 10.5 Analyses Associated with the Secondary Objective[s]). In this section, describe statistical methods that will be used to analyse relevant safety outcomes, including any AESI. This should typically include specification of a measure to estimate risk within treatment arms, a measure to compare risks across treatment arms, and a measure of statistical uncertainty around the comparison such as a confidence interval.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.7",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.7 Safety Analyses\nConcept: CNEW",
        "repeating": "No"
    },
    "Other Analyses": {
        "name": "Other Analyses",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the analyses that are different than the one(s) previously specified or mentioned.",
        "guidance": "Describe other analyses not included in Sections 10.3-10.8, such as subgroup analyses.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.8",
        "value": "Text ",
        "business_rules": "Value AllowedYes\nRelationship: 10.8 Other Analyses,Concept: CNEW",
        "repeating": "No"
    },
    "Interim Analyses": {
        "name": "Interim Analyses",
        "data_type": "Text",
        "definition": "C142582\nFor review purpose, see definition of the controlled terminology below\nA textual description of any analysis intended to compare treatment arms with respect to efficacy or safety at any time prior to the formal completion of a trial.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.9",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.9 Interim Analyses\nConcept: C142582",
        "repeating": "Yes, repeatable for each interim"
    },
    "Multiplicity Adjustments": {
        "name": "Multiplicity Adjustments",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA textual description of the statistical adjustments needed to limit the probability of false positive findings in trials where there are multple simultaneous hypotheses.",
        "guidance": "Multiple testing procedures may be needed to limit the probability of false positive findings in a trial. Reasons for carrying out multiple statistical tests include - but are not restricted to - multiple endpoints, multiple treatment groups, multiple hypotheses, subgroups, different statistical methods, etc.\nDescribe any approaches to multiplicity control for the trial. This description might go beyond the analysis of primary objectives.\nSpecify the statistical approach to control the overall type I error rate as well as the (adjusted) significance levels to test specific hypotheses, as applicable. Clarify whether the tests/confidence intervals are one- or two-sided.\nState the circumstances under which a study will be considered to have met its primary objective(s). For example, in a study with two primary efficacy endpoints, this section should state whether the study would be expected to provide evidence on at least one or on both of the endpoints in order to confirm the efficacy of the treatment.\nFor some statistical approaches it might be helpful to include a graphical depiction, as visualisation will be helpful for understanding, coupled with the clinical translation of the mathematical choices.\nDetails regarding Interim Analyses should be provided in section 10.9.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.10",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:10.10 Multiplicity Adjustments\nConcept: CNEW",
        "repeating": "No"
    },
    "Sample Size Determination": {
        "name": "Sample Size Determination",
        "data_type": "Text",
        "definition": "C115467\nFor review purpose, see definition of the controlled terminology below\nA statistical calculation to determine the number of subjects required for the primary analysis, which should be large enough to provide a reliable answer to the questions addressed and should be determined by the primary objective of the trial. If the sample size is determined on some other basis, then this should be made clear and justified.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "10.11",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 10.11 Sample Size Determination,\nConcept: C115467",
        "repeating": "No"
    },
    "Regulatory and Ethical Considerations": {
        "name": "Regulatory and Ethical Considerations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nCareful thought or deliberation related to the regulatory and ethical aspects of the trial.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.1 Regulatory and Ethical Considerations\nConcept: CNEW",
        "repeating": "No"
    },
    "Trial Oversight ": {
        "name": "Trial Oversight ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the planned processes and procedures to govern and conduct a clinical trial in order to protect the rights, safety and welfare of the trial participants.",
        "guidance": "Concisely summarize the trial oversight listing the investigator and sponsor responsibilities not covered in other sections of the protocol which are essential for the operations of the trial, specifying the ones related to quality assurance.\nif not using below optional subheadings",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "11.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.2 Trial Oversight\nConcept: CNEW",
        "repeating": "No"
    },
    "Investigator Responsibilities": {
        "name": "Investigator Responsibilities",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to the trial.",
        "guidance": "",
        "conformance": "Optional ",
        "cardinality": "One to one ",
        "relationship": "11.2.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.2.1 Investigator Responsibilities\nConcept: CNEW",
        "repeating": "No"
    },
    "Sponsor Responsibilities": {
        "name": "Sponsor Responsibilities",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the sponsor with respect to the trial.",
        "guidance": "",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "11.2.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.2.2 Sponsor Responsibilities\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Informed Consent Process": {
        "name": "Description of Informed Consent Process",
        "data_type": "Text",
        "definition": "C184390\nFor review purpose, see definition of the controlled terminology below\nThe procedure by which informed consent is obtained and documented by means of a written, signed, and dated informed consent form. This process may include obtaining assent from participants with legally authorised representatives.",
        "guidance": "Specify the key elements of the informed consent process, including any special needs and how these are addressed (e.g., assent, capacity, legally acceptable representative, adolescents who may reach age of majority during the trial, pregnant participants and pregnant partners of participants).",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.3",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: C184390",
        "repeating": "No"
    },
    "Description of Assent Process": {
        "name": "Description of Assent Process",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA  of the assent process for those individuals unable to give informed consent on their own behalf, to participate in the trial.",
        "guidance": "N/A",
        "conformance": "Optional",
        "cardinality": "One to one",
        "relationship": "11.3",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
        "repeating": "No"
    },
    "Description of Emergency Consent Process": {
        "name": "Description of Emergency Consent Process",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA type of informed consent process that may occur during an emergency situation in which the participant or their legally authorised representative is not available to give consent.",
        "guidance": "If enrollment in the trial may occur during an emergency in which the participant or their legally acceptable representative is not able or available to give consent, describe the consent process.",
        "conformance": "Optional",
        "cardinality": "One to one ",
        "relationship": "11.3",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.3 Informed Consent Process\nConcept: CNEW",
        "repeating": "No"
    },
    "Consent for Rescreening": {
        "name": "Consent for Rescreening",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for participants in the event of screen failure and rescreening.",
        "guidance": "If participants can be rescreened, state whether the participant needs to complete a new consent. Screen failure and rescreening should be clearly defined in the protocol, with cross-reference to those definitions.",
        "conformance": "",
        "cardinality": "One to one",
        "relationship": "11.3.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.3.1 Informed Consent for Rescreening\nConcept: CNEW",
        "repeating": "No"
    },
    "Informed onsent for Use of Remaining Samples in Exploratory Research": {
        "name": "Informed onsent for Use of Remaining Samples in Exploratory Research",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the consent requirements for exploratory research using the remainder of mandatory samples. If applicable, this may include text in the original consent that address the use of remaining samples or additional text.",
        "guidance": "If participants will be asked to consent to optional exploratory research using the remainder of mandatory samples, describe the use of remaining samples for optional exploratory research.\nIf any exploratory research is planned and additional written consent regarding the use of remaining samples for exploratory research will be obtained, describe the consent process.",
        "conformance": "",
        "cardinality": "One to one ",
        "relationship": "11.3.2",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.3.2 Informed Consent for Use of Remaining Samples in Exploratory Research\nConcept: CNEW",
        "repeating": "No"
    },
    "Committees": {
        "name": "Committees",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the type and administrative structure of any committee associated with the trial.",
        "guidance": "Briefly describe the administrative structure of committees that will be reviewing data while the trial is ongoing, and the type of committee (e.g., Dose Escalation Committee, Data Monitoring Committee or Data Safety Monitoring Board). Note that specific details may be required depending on local law or regulation. If applicable, Committee Charters may be cross-referenced. If no committees are applicable, state \u201c applicable.\u201d",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.4",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.4 Committees\nConcept: CNEW",
        "repeating": "No"
    },
    "Insurance and Indemnity": {
        "name": "Insurance and Indemnity",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA concise summary of the arrangements for participants insurance and indemnity as required by the applicable regulatory body.",
        "guidance": "Concisely summarize the arrangements for participants insurance and indemnity if not addressed in a separate agreement, if required by the applicable regulatory requirements.",
        "conformance": "Required",
        "cardinality": "One to ",
        "relationship": "11.5",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.5 Insurance and Indemnity\nConcept: CNEW",
        "repeating": "No"
    },
    "Risk Management": {
        "name": "Risk Management",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of how potential risks and critical to quality factors associated with the trial will be handled.",
        "guidance": "",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.6",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.6 Risk Management\nConcept: CNEW",
        "repeating": "No"
    },
    "Data Governance": {
        "name": "Data Governance",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the key processes to ensure data integrity, traceability and security, in order to enable accurate collection, reporting, monitoring, transfer, retention, access and publication.",
        "guidance": "\n",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.7",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.7 Data Governance\nConcept: CNEW",
        "repeating": "No"
    },
    "Source Data Introduction": {
        "name": "Source Data Introduction",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of trial-related source data including the importance of source data maintenance and expectations for data traceability.",
        "guidance": "Establish the importance of source data and expectation for traceability of transcribed information back to source. Delineate expectations for investigators (e.g., maintain source data at the site, ensure availability of current records) and trial monitors (e.g., verify CRF data relative to source, ensure that safety of participants is being protected and that conduct is in accordance with GCP). what constitutes source data and its origin or provide a reference to the location of , if contained in a separate document, such as a monitoring guideline or source data acknowledgement).\nDescribe the provision for direct access to source data and documents enabling clinical trial-related monitoring, audits and regulatory inspections, if not included in separate agreement(s).",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
        "repeating": "No"
    },
    "Investigator Expectations for Source Data": {
        "name": "Investigator Expectations for Source Data",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the investigator with respect to maintaining and ensuring availability of the source data.",
        "guidance": "N/A",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
        "repeating": "No"
    },
    "Trial Monitor Expectations for Source Data": {
        "name": "Trial Monitor Expectations for Source Data",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the obligations of the trial monitor with respect to maintaining and ensuring availability of the source data.",
        "guidance": "N/A",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11.Source Data\nConcept: CNEW",
        "repeating": "No"
    },
    "of Source Data": {
        "name": "of Source Data",
        "data_type": "Text",
        "definition": "C125442\nFor review purpose, see definition of the controlled terminology below\n",
        "guidance": "N/A",
        "conformance": "Required",
        "cardinality": "One to one ",
        "relationship": "11.",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: 11. Source Data\nConcept: C125442",
        "repeating": "No"
    },
    "Protocol Deviations": {
        "name": "Protocol Deviations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of plans for detecting, reviewing, and reporting any deviations from the protocol.",
        "guidance": "Describe plans for detecting, reviewing, and reporting any deviations from the protocol or include reference to a separate document.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:  Protocol Deviations\nConcept: CNEW",
        "repeating": "No"
    },
    "Decision Rights for Site Closure": {
        "name": "Decision Rights for Site Closure",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of the legal principles of entitlement for the sponsor to close a trial site, or for the investigator to initiate the closure of a trial site.",
        "guidance": "List the sponsor\u2019s rights to close a site early. Likewise, list the investigator\u2019s rights to initiate early site closure.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
        "repeating": "No"
    },
    "Criteria for Early Closure": {
        "name": "Criteria for Early Closure",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe requirements that must be met in order to close a trial site prematurely.\n",
        "guidance": "List the criteria for early closure of a site by the sponsor or investigator.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
        "repeating": "No"
    },
    "Responsibilities Following Early Site Closure": {
        "name": "Responsibilities Following Early Site Closure",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe responsibilities of the sponsor and/or investigator following an unplanned early termination or suspension of the trial at an individual site.",
        "guidance": "List the responsibilities of the sponsor and investigator following early site closure, such as informing the ethics committee(s), and prompt notification of the participant and their transition to appropriate therapy and/or follow-up.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship:  Early Site Closure\nConcept: CNEW",
        "repeating": "No"
    },
    "Clinical Laboratory Tests": {
        "name": "Clinical Laboratory Tests",
        "data_type": "Text",
        "definition": "C25294\nFor review purpose, see definition of the controlled terminology below\nAny procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.",
        "guidance": "Specify which laboratory parameters should be included in each clinical laboratory assessment panel (e.g., for haematology, chemistry, urinalysis). A tabular presentation for such information is common. If applicable, include equations and references for locally calculated laboratory results. \nIf not applicable, retain heading and enter \u201cNot applicable.\u201d",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "12.1",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 12.1 Clinical Laboratory Tests\nConcept: C25294",
        "repeating": "No"
    },
    "CountryRegionSpecific Requirements": {
        "name": "CountryRegionSpecific Requirements",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific requirements related to the trial but not related to individual items in the protocol.",
        "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
        "conformance": " If there is Country/Region-specific differences",
        "cardinality": "One to many",
        "relationship": "12.2",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: CNEW",
        "repeating": "Yes, repeatable for each Country/Region"
    },
    "CountryRegionspecific Protocol Clarification": {
        "name": "CountryRegionspecific Protocol Clarification",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA description of any country or region-specific clarifications related to a protocol item.",
        "guidance": "Although global clinical trial practices are increasingly harmonised, some country/ region-specific differences in requirements do exist (e.g., document retention periods, contraception requirements). Where differences in requirements cannot be reconciled, sponsors should explain how they will document and communicate country/region-specific differences (e.g., by country/region-specific amendments or addenda).\nAn alternative to country/region-specific amendments is to list the specific differences by country or countries in this section, including a reference to the relevant section of the protocol where the differing requirement applies.",
        "conformance": " if there is Country/Region-specific differences",
        "cardinality": "One to many",
        "relationship": "12.2 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 12.2 Country/Region-Specific Differences\nConcept: CNEW",
        "repeating": "Yes, repeatable for each country/region"
    },
    "Approval Date ": {
        "name": "Approval Date ",
        "data_type": "Date",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe date that the sponsor approved the version of the protocol, ",
        "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
        "conformance": "Conditional: if amendment",
        "cardinality": "One to one",
        "relationship": "12.3",
        "value": "Date",
        "business_rules": "Value Allowed: Yes\nRelationship: The Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
        "repeating": "Yes, repeatable one table per amendment"
    },
    " or  enrolled globallylocallyper cohort": {
        "name": " or  enrolled globallylocallyper cohort",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage. The numeric value for the estimated number of participants enrolled in the trial, expressed as an absolute value or percentage.",
        "guidance": "",
        "conformance": ": when there is an amendment",
        "cardinality": "One to one",
        "relationship": "12.3",
        "value": "<# or %> enrolled <globally/locally/per cohort>",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
        "repeating": "Yes, reuse from the title page"
    },
    " or ": {
        "name": " or ",
        "data_type": "Number",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nThe numeric value (expressed as an absolute value or percentage) for the estimated number of participants enrolled at the time of the protocol amendment.",
        "guidance": "N/A",
        "conformance": " if Original Protocol =No",
        "cardinality": "One to one",
        "relationship": "Amendment Details",
        "value": "Integer for Number or one decimal point for percent",
        "business_rules": "Value Allowed: Yes\nRelationship: \u201d\nConcept: CNEW",
        "repeating": "Yes, reuse from the title page"
    },
    "specify alternative location ": {
        "name": "specify alternative location ",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nthe physical or virtual location of the date on which the sponsor approved the current version of the protocol.",
        "guidance": "N/A",
        "conformance": "Conditional: when a specify alternative location is selected",
        "cardinality": "One to one",
        "relationship": "12.3",
        "value": "Text Location where information can be found",
        "business_rules": "Value Allowed: Yes\nRelationship: \nConcept: CNEW",
        "repeating": "Yes, reuse from the title page."
    },
    "amendment number": {
        "name": "amendment number",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA sequence of characters used to uniquely identif a protocol amendment",
        "guidance": "Move the Overview of Changes table from the previous amendments to this section in reverse chronological order (most recent first).",
        "conformance": "Conditional: if amendment",
        "cardinality": "One to one",
        "relationship": "12.3",
        "value": "Text ",
        "business_rules": "Value Allowed: Yes\nRelationship: Overview of Changes from each prior protocol amendment is {provided below} or <specify alternative location>}.\nConcept: CNEW",
        "repeating": "Yes, repeatable one table per amendment"
    },
    "Glossary of Terms and Abbreviations": {
        "name": "Glossary of Terms and Abbreviations",
        "data_type": "Text",
        "definition": "CNEW\nFor review purpose, see definition of the controlled terminology below\nA collection of abbreviations (a shortened form of a word or phrase) and definitions (a concise explanation of the meaning of a word or phrase or symbol).",
        "guidance": "Define abbreviations and other terms used in the protocol. A tabular presentation is common and may serve as the definition at first use.",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "13",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 13 APPENDIX: GLOSSARY OF TERMS AND ABBREVIATIONS\nConcept: CNEW",
        "repeating": "No"
    },
    "References": {
        "name": "References",
        "data_type": "Text",
        "definition": "C184397\nFor review purpose, see definition of the controlled terminology below\nThe curated list of sources that are cited within the reference section of the document.",
        "guidance": "References should be listed in a common format that includes all relevant information to identify the source and date published. If not published, this should be clearly indicated. ",
        "conformance": "Required",
        "cardinality": "One to one",
        "relationship": "14 ",
        "value": "Text",
        "business_rules": "Value Allowed: Yes\nRelationship: 14 APPENDIX: REFERENCES\nConcept: C184397",
        "repeating": "No"
    }
}